Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
5-27-2020 4:00 PM

Quadriceps Muscle Layer Thickness in Kidney Transplant
Recipients: A Potential Measure of Frailty and Sarcopenia
Max A. Levine, The University of Western Ontario
Supervisor: Luke, Patrick P., The University of Western Ontario
Co-Supervisor: Madill, Janet, Brescia College
Joint Supervisor: Sener, Alp, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Surgery
© Max A. Levine 2020

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Musculoskeletal System Commons, Surgery Commons, and the Urogenital System
Commons

Recommended Citation
Levine, Max A., "Quadriceps Muscle Layer Thickness in Kidney Transplant Recipients: A Potential Measure
of Frailty and Sarcopenia" (2020). Electronic Thesis and Dissertation Repository. 7004.
https://ir.lib.uwo.ca/etd/7004

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Introduction: Frailty and sarcopenia are related concepts that can impact outcomes after
kidney transplantation. Measures of these two entities and new/emerging metrics of
sarcopenia remain to be validated.
Methods: In a prospective cohort study, kidney and kidney-pancreas transplant recipients
were assessed at the time of transplant with the Physical Frailty Phenotype, bioimpedance
analysis, quadriceps muscle layer thickness (QMLT), and CT. The impact on length of stay
(LOS), prediction of frailty/sarcopenia, and relative concordance of metrics were analyzed.
Results: Low QMLT, a putative surrogate of sarcopenia/frailty, was more frequently
associated with longer LOS (>14 days) after transplant. Additionally, QMLT was predictive
of low muscle mass but insufficient at discriminating true sarcopenia, while CT of the
abdominal muscles at the L3 level showed good discrimination for sarcopenia.
Conclusions: Further exploration of QMLT and cut-offs for CT and functional metrics in the
transplant population are required for future studies and risk stratification.

Keywords
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Fried Frailty Index, Frailty Phenotype, Kidney Pancreas Transplant, Quadriceps Muscle
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Summary for Lay Audience
Kidney failure leaves patients dependent upon either dialysis or kidney transplant to stay
alive. While waiting for transplant, patients can become frail due to age, co-morbid disease,
or kidney failure itself. Frailty leads to susceptibility to disease and complications from
illness and surgery. Underpinning frailty is sarcopenia, or the loss of muscle characterized by
both loss of muscle mass, and strength; having good strength with lower overall muscle mass
does not make one sarcopenic.
The relationship between frailty, sarcopenia and the outcomes of kidney transplant, were
explored. We studied the utility of using ultrasound measurement of thigh muscles to see if
muscle thickness could identify frailty and sarcopenia, and if it could predict how long
someone stayed in hospital after transplant. Overall, people with thicker/more muscle had
shorter stays in hospital than those with less muscle in the thighs, with an average of 4 days
less in hospital (8 vs. 12 days). While significant, those with thicker thigh muscles more
often had someone donate a kidney to them, rather than receiving a deceased donor kidney. It
is known that living donor recipients have shorter hospital stays, so the impact of thigh
muscle thickness is difficult to interpret. Thigh muscle thickness was not clearly associated
with frailty, but it did show correlation with low overall muscle mass. Despite this, thigh
muscle thickness did not reliably predict sarcopenia, which relies on both muscle mass and
function.
Valid measures for identifying sarcopenia in those undergoing transplant are evolving, so we
explored how well different measures of sarcopenia compared to CT scan data. We
measured the total cross sectional area of the muscles in the torso/core and compared these
values to our other measures of muscle (using a body composition analyzer), and strength
and walking speed as measures of muscle function. CT provided a relatively good ability to
identify sarcopenia (both low muscle mass and strength), with analysis of a single CT
picture. This holds promise for refining how we identify patients with sarcopenia in both
research and clinical practice with the aim to provide ways of treating/preventing sarcopenia
in the future.
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Chapter 1

1

Renal Transplantation, Frailty, and Sarcopenia

1.1 Brief primer on renal transplantation
End stage renal disease (ESRD) is a chronic health state leaving patients dependent on
one of several forms of renal replacement therapy, with initiation of dialysis as the most
common and accessible form. The gold standard of renal replacement is kidney
transplantation due its impact on longevity, quality of life, and cost-savings.1-4 As
medical care advances, the population of patients on dialysis awaiting a kidney transplant
has overall become older, sicker, and made to wait longer for a transplant than initial
reports on the benefits of transplant.3 Despite this, the improved outcomes of
transplantation relative to remaining on dialysis are still seen in contemporary studies of
transplant outcomes.3 Recent data suggest that even in the elderly transplant recipients,
the overall risk of death may be reduced up to 61% compared to remaining on dialysis,
and is associated with an improved life expectancy overall.5
The number of patients awaiting a kidney transplant is high, and continues to grow. The
Canadian Organ Replacement Register (CORR) reported 3,106 adults in Canada were on
the wait list for a kidney transplant in 2017 (with this number increasing year over year),
while 38,833 were living with ESRD overall.6 The rate of kidney transplantation has
increased over the last decade, but the number of patients remaining on the wait list
remains stable4:
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Figure 1. Relationship between the number of kidney transplants performed and
the number remaining on the waitlist in Canada
Terner, M., et al. (2016). "Increasing Rates of Kidney Failure Care in Canada Strains Demand for Kidney Donors."
Healthc Q 19(3): 10-12.

Given the relative scarcity of access to transplantable kidneys, the priority to optimize
outcomes becomes self-evident.
The transplant procedure classically involves an extraperitoneal dissection of the
pelvic/lower abdominal vasculature with temporary interruption of blood flow to the
lower limb, vascular anastomosis, and establishment of urinary drainage, most often via
anastomosis to the native bladder or ureter. Surgery-induced physiologic stress can be
significant, with induction of anesthesia, extensive abdominopelvic dissection, and
significant fluid shifts. In a recent Canadian report, the rates of Clavien-Dindo Grade 2
or greater complications post-transplant were found to be 60%, with 15% experiencing
complications Grade 3b or worse.7 With the ESRD population waiting longer for
transplant, and the average age of this population increasing, careful consideration should
be paid to identifying factors that may predispose to poorer outcomes, with the aim of
mitigating complications via improved patient selection, risk counselling and
stratification, and potentially interventions to alter risk.
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1.2 Review of the Literature
1.2.1

Frailty

The concept of frailty has become an established and refined clinical term, initially
arising from the geriatrics literature. Frailty is a complex construct, but has become
generally understood and appreciated as a state that represents a loss of physiologic
reserve or physiologic dysregulation.8 In general, the presence of frailty is considered to
represent a general inflammatory state that may be associated with a reduced ability to
withstand physiologic insults associated with disease.8-10 Fried and colleagues (2001)
contributed significantly to the establishment of a contemporary framework for defining
frailty. Frailty had previously been considered similar to being old, disabled, or otherwise
lacking potential for longevity, but in recent years has been more accurately defined as a
measurable phenotype of an underlying syndrome.11 This geriatric syndrome has been
explored to not only identify patients at risk, but to also differentiate frailty from comorbidity, as the two concepts are related but not interchangeable.11,12

The Frailty Phenotype, commonly referred to as the Fried score, Fried Phenotype, or
Physical Frailty Phenotype, defines patients as frail if they possess 3 or more of the
following attributes: shrinking (unintended weight loss of ≥ 10 pounds in the prior year),
weakness (measured by hand grip strength compared to the weakest 20% of the
population), poor endurance or energy (based on self-report of exhaustion), slowness
(measured by 15 foot walk test compared to the slowest 20% of the population), low
physical activity (a weighted score of energy expenditure per week derived from
participant report of activity levels).11 Those possessing 2 attributes are considered prefrail, and those with 0-1 are non-frail. Based on data from the Cardiovascular Health
Study, a prospective observational study of 5,201 men and women over 65, these five
components of the Frailty Phenotype were validated as predictors of falls, worsening
mobility, incident hospitalization, and death.11
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Other means of quantifying frailty exist and are used in clinical practice. Alternative
frailty instruments provide clinical practitioners with options that come with their own
relative strengths and weaknesses.12 The Fried score allows for distinct categorization
(non-frail, pre-frail, frail) based on an assigned score derived from reported symptoms
and performance on tests.8,11 A competing frailty instrument, developed in a similar
vintage, is the Clinical Frailty Scale.13 The Clinical Frailty Scale (CFS) was derived from
data in the Canadian Study of Health and Aging, whereby the initial quantification of
frailty began with scoring based on an a priori list of clinical deficits (70 in total), and
through several iterations of assessment a 7-point scale was created to score frailty
based on clinical judgement of a healthcare practitioner.13

Figure 2. Clinical Frailty Scale
Rockwood, K., et al. (2005). "A global clinical measure of fitness and frailty in elderly people."
CMAJ 173(5): 489-495.
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A unifying definition of frailty, and the best way to quantify this concept, remains a work
in progress.12 The relative merits of different approaches to measuring frailty should be
considered when applying such instruments to clinical or research scenarios. Overall, the
Fried frailty phenotype represents the most often utilized frailty score in the literature.

1.2.1.1

The impact of Frailty on ESRD

While frailty and co-morbidity are distinct concepts, there remains considerable overlap
between the “frail” and “co-morbid” populations. One such population of interest
include those living with chronic kidney disease (CKD). CKD patients, and especially
those with end-stage renal disease (ESRD), are in an extremely vulnerable health state.
Given that frailty is often considered an inflammatory state, and ESRD is also associated
with chronic inflammation, a shared pathophysiology becomes evident or at least
plausible.10 In a systematic review by Chowdhury and colleagues (2017), the relationship
between frailty and CKD was explored.10 In this review, most studies examining frailty
in the setting of CKD have utilized the Fried phenotype, with 27 of 32 studies using it as
their determinant of frailty. Despite the apparent consensus on its use, there were several
variations of its use, with alternative interpretations of the components of the phenotype.
The second most common metric of frailty was the CFS, employed by 3 of the 32
reviewed studies. Other instruments used included the FRAIL scale, Groningen Frailty
Indicator, Montensanto approach, Edmonton Frail Scale, and frailty checklist.10 When
the Fried score was used to assess frailty, the prevalence of frailty ranged from 14-73% in
dialysis dependent populations. The vast discrepancy between studies is attributed to
modifications of the Fried scoring system, where patient reported scores in place of
objective measurements are thought to over-estimate the prevalence of frailty.10

The relationship between renal dysfunction and frailty has been demonstrated in large
prospective studies. Dalrymple et al (2013) examined the relationship between degree of
renal dysfunction and both prevalent and incident frailty. Drawing from the population in
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the Cardiovascular Health Study (community dwelling adults over the age of 65, without
evidence of Alzheimer disease, Parkinson disease, stroke), 4,150 individuals were
stratified by renal function to define the population exposure of interest, and the outcome
of frailty was assessed at two time points. Renal function (eGFRcys) was quantified by
the 2008 CKD-EPI cystatin-c equation, and frailty by the original Fried phenotype score.
Prevalent frailty was quantified at a specific time point in the longitudinal study, and
incident frailty derived 4 years after. The relationship between renal function and
prevalent frailty was strong, with decreasing eGFRcys associated with higher rates of
frailty14:

Figure 3. The prevalence of frailty stratified by level of kidney function
Dalrymple, L. S., et al. (2013). "Kidney function and prevalent and incident frailty." Clin J Am Soc
Nephrol 8(12): 2091-2099.

Incident frailty followed a similar trend. Logistic regression analysis estimated an
adjusted incidence rate ratio for frailty of 3.08 in those with eGFRcys 15-44
mL/min/1.73m2 compared to those with eGFRcys ≥ 90 mL/min/1.73m2. These findings
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lend support to a shared pathophysiology between CKD and frailty, since the onset of
frailty was not heralded by the initiation of dialysis in this population. Clearly, frailty sets
in prior to the need for renal replacement.14

The prevalence of frailty at the time of dialysis initiation has also been described. Bao
and colleagues (2012) reported on a population undergoing dialysis initiation in an effort
to delineate if frailty drove dialysis initiation at higher relative eGFR levels.15 In this
examination of data from the Comprehensive Dialysis Study, prospective assessment of
incident maintenance dialysis was related to frailty phenotype at the time of initiation.
Frailty was assessed using a modified version of the Fried phenotype that had been
published previously, whereby weight loss was omitted due to non-capture of data,
slowness and weakness defined by a score of <75 on the physical functioning scale of the
SF-12 survey, and exhaustion criterion defined by responses to other items on this
survey. The overall prevalence of frailty was 73% in this population, with a prevalence
of 63% in patients under 40 years of age. Being frail was significantly associated with a
higher mean eGFR at initiation of dialysis (10.4 vs 8.8 mL/min/1.73m2) as well as a
higher risk of death (HR = 1.57 at median 2.9 years of follow up). The higher eGFR at
initiation of dialysis may represent the misappropriation of symptoms as uremic
complications as opposed to manifestations of frailty.15 On the other hand, uremia may
be contributory to the clinical phenotype that defines frailty according to the Fried score.
These authors estimate that the difference in eGFR at the time of dialysis initiation
translates to an average of 3 additional dialysis free months in the non-frail.15

1.2.1.2

The impact of Frailty on Kidney Transplant Outcomes

The impact of kidney transplantation on outcomes in ESRD is well appreciated, with
demonstrable improvements in quantity and quality of life.1-3 Overall, these benefits of
kidney transplant are seen in frail populations as well9, but frailty may influence the
outcomes of those undergoing transplantation. It has been demonstrated in a multi-centre
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cohort study of patients on the waitlist for kidney transplant that those deemed frail using
the Fried phenotype experience a significantly increased risk of waitlist mortality (HR =
2.19).16

The impact of frailty on outcomes post-transplant are manifold. In a prospective study of
183 patients with ESRD at a single institution, Garonzik-Wang and colleagues (2012)
demonstrated that frailty predicted the occurrence of delayed graft function (DGF) in
kidney transplant recipients.17 These authors found the prevalence of frailty (defined
using the Fried phenotype) to be 25% in their population of patients undergoing kidney
transplant. Frailty was associated with a DGF rate of 30% compared to a DGF rate of
15% in the non-frail. After adjustment for donor and recipient confounders, the relative
risk of DGF was calculated at 1.94. Interestingly, the effect of frailty was found to be
independent of age.17 This reinforces the idea that frailty is related to but not entirely
driven by age. An explanation for the relationship between frailty and DGF is thought to
be due to systemic inflammation17, as frailty represents a manifestation of a proinflammatory state and DGF may be related to pre-transplant inflammation.18 The
influential role of frailty on rates of DGF may potentially contribute to risk stratification
as well as refine perioperative risk counselling.

Further examination of the potential influence of frailty on kidney transplant outcomes
has taken place in the intermediate post-operative period as well. A prospective cohort
analysis by McAdams-DeMarco et al (2013) found that frailty predicted early readmission to hospital after kidney transplant. In their cohort of 383 kidney transplant
recipients, the authors found that frail recipients, assessed by the Fried phenotype, were
more likely to experience early hospital readmission, defined as ≥1 hospitalizations
within 30 days of discharge (46 vs 28%). After adjustment for several possible
confounders including sex, age, BMI, donor factors, and immunologic risk, frailty
conferred an adjusted risk ratio of 1.61 for the occurrence of early readmission.19
Consistent with other reports, the impact of frailty did not differ with age. When these
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authors added frailty to a previously published registry-based model to predict
readmission post-transplant, the receiver operator area under the curve was significantly
higher with the addition of frailty to the model.19 Again, frailty represents a measurable
factor that can help further risk stratify kidney transplant recipients as well as those who
are pending transplant.

Length of stay after transplant has also been shown to be influenced by frailty in a hybrid
registry-augmented analysis.20 Using data (74,859 patients) from the Scientific Registry
of Transplant Recipients, risk factors for prolonged length of stay were assessed with
precise estimated coefficients, identifying both recipient and donor factors that predicted
prolonged stay in hospital. The authors then linked this registry data with their local
cohort of 589 transplant recipients with the added variable of frailty, measured by the
Fried score, and used the constrained coefficients of the known predictive factors to
estimate the independent influence of frailty. Frail kidney transplant recipients had a
1.14-fold longer length of stay on average, and had a 1.6-fold greater likelihood of
hospitalization beyond 2 weeks.20 This novel data analysis model provided granular
estimation of risk from confounding factors affecting length of stay while allowing for
the emergence of frailty as an independent risk factor for increased length of stay.

The impact of frailty on kidney transplant outcomes goes further, with implications for
mortality as well. In a similar hybrid registry-augmented model described above, the
same group of authors identified frailty as being an independent predictor of mortality in
the kidney transplant recipient population.21 After adjusting for relevant confounders,
transplant recipients deemed frail by the Fried score carried 2.17-fold increased risk of
mortality compared to their non-frail counterparts.21 As has been seen in the general
elderly and CKD populations, the impact of frailty on mortality persists after transplant.
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An important consideration regarding frailty is the potentially dynamic nature of the
phenotype. Chu et al (2019) reviewed frailty scores in a cohort of 569 transplant
recipients assessed both at the time of transplant evaluation and at the time of transplant.
The authors categorized patients’ change in frailty status in one of three ways: binary
(frail/non-frail), a 3-category state (frail/intermediate/non-frail), or raw frailty score
change. At a median of 1.1 years between assessment and transplant, 22% of recipients
became more frail, 24% became less frail, and 54% remained stable in their frailty
category. Those who became more frail had a greater than 2-fold increased risk of
mortality and hospital stay ≥2 weeks after transplant compared to those who remained
stable in their frailty state. Additionally, drivers of worsening frailty seemed to relate to
age, history of diabetes, and cause of ESRD.22 While half of patients remained in their
frailty category between the time of assessment and transplant, a balanced number
worsened or improved. This highlights the potential for frailty to change over time, and
suggests serial evaluation may be required if frailty is to be used for risk stratification for
transplant. Understanding the pathophysiologic contributors to frailty may allow
targeting of modifiable factors underlying patients’ frail states, potentially improving
longevity and outcomes of transplantation.

1.2.1.3

Biologic Mechanisms of Frailty

The biologic basis for the clinical phenotype of frailty is complex, but is becoming better
elucidated over time. Exterkate and colleagues (2016) reviewed the impact of frailty on
kidney transplant outcomes, highlighting the evidence for underlying pathophysiologic
mechanisms. In their review, the authors note several unifying mechanisms for frailty
relating to cellular senescence and a resultant impaired homeostasis, with eventual
dysregulation of both energy metabolic systems and the neuromuscular system.5
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Figure 4. The relationship of possible risk factors and clinical states contribuitng to
frailty in the ESRD population
Exterkate, L., et al. (2016). "Frailty and Transplantation." Transplantation 100(4): 727-733.

Their review describes the immunologic sequelae of frailty, underpinned by evidence of
systemic inflammation in the form of heightened levels of Interleukin 6 (IL-6), Interferon
gamma (IFN-gamma), and C-reactive protein (CRP). These authors also describe
specific immune changes that they consider a hallmark of frailty, including elevated
amounts of CD8+ T cells and a lower CD4+:CD8+ ratio, as well as several other
alterations in T cell surface markers.5 Although the clinical significance of these
variations in cell surface markers in frail patients is not fully understood now, it stands to
reason there may be a potential interplay between frailty and immunologic response to
transplant.
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1.2.2
1.2.2.1

Sarcopenia
Definitions and Pathophysiology of Sarcopenia

Skeletal muscle comprises a significant proportion of an individual’s lean body mass, and
accounts for approximately half of the body’s total protein energy stores23; the loss of
lean muscle mass has been termed sarcopenia. As protein is an essential component to the
normal function of all organs and organ systems, protein reserves are sometimes called
upon to supplement protein and amino acids in states of decreased protein intake or
inflammatory disease states.23 Aging in and of itself represents a significant contributor
to sarcopenic changes. “Sarcopenia of aging” is the term granted to age related muscle
loss, and begins early in life, with an estimated 0.1-0.5% muscle mass decline per year
beginning at age 30, with significant acceleration after age 65.24 The prevalence of
sarcopenia has been estimated at between 5-50% in the elderly general population.25 No
standard or widely accepted definition of sarcopenia existed for several years, but the
European Working Group on Sarcopenia in Older People (EWGSOP) in 2010 created a
practical clinical definition as follows: “a syndrome characterized by progressive and
generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes
such as physical disability, poor quality of life, and death”.24,26 To this end, this group
proposed a conceptual staging tool for the presence of sarcopenia including the following
criteria: 1) Low muscle mass, 2) Low muscle strength, and 3) Low physical
performance.26 The presence of criteria 1 alone, as measured by some means that
accurately estimates muscle mass with comparators to population norms, indicated
‘presarcopenia’. ‘Sarcopenia’ was therefore deemed present when criterion 1 was found
in conjunction either criteria 2 or 3, and the presence of all three indicating ‘Severe
sarcopenia’.26 Since the proposal of this framework, several other international groups
focusing on sarcopenia have provided operational definitions for sarcopenia. There is
significant agreement and overlap of these groups’ definitions of sarcopenia.27
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Figure 5. Comparisons of different sarcopenia definitions in the literature
Morley, J. E., et al. (2014). "Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers,
and epidemiology-update 2014." J Cachexia Sarcopenia Muscle 5(4): 253-259.

The underlying mechanisms leading to sarcopenia have been described by the EWGSOP
and is summarized in the flow diagram below.26 Sarcopenia represents a manifestation of
multiple contributors ranging from lifestyle factors, aging, and sequelae of certain disease
states. Furthermore, the EWGSOP suggests sarcopenia can be categorized by etiology,
differentiating primary causes (age-related sarcopenia) and secondary causes (sarcopenia
of inactivity, disease-associated sarcopenia, nutrition-related sarcopenia).26
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Figure 6. Demonstration of multiple underlying etiologies contributing to sarcopenia
Cruz-Jentoft, A. J., et al. (2010). "Sarcopenia: European consensus on definition and diagnosis:
Report of the European Working Group on Sarcopenia in Older People." Age Ageing 39(4): 412-423

Further evidence since the initial EWGSOP consensus on sarcopenia has led to an
updated framework for the diagnosis of sarcopenia. The EWGSOP2 met in 2018 to
update the definition of sarcopenia to be based on the incipient criteria of low muscle
strength, with confirmation of the diagnosis heralded by the presence of either low
muscle quantity, and/or low physical performance.28 Muscle strength may be assessed by
grip strength or chair stand test. Muscle quantity can be measured using dual energy Xray absorptiometry (DEXA), whole body or appendicular skeletal muscle mass predicted
by bioimpedance analysis, lumbar muscle cross-sectional area by CT or MRI. Physical
performance is assessed using gait speed, Short physical performance battery, Timed-upand-go test, or 400-meter walk test.28
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In the CKD population specifically, sarcopenic mechanisms have been explored to better
understand the pathophysiology of this phenomenon. The metabolic acidosis inherent to
CKD disease states leads to activation of the ubiquitin-proteasome degradation pathways,
while elevated angiotensin II levels can activate the caspase-3 pathways and causes a
reduction in skeletal Insulin-like Growth Factor 1 (IGF-1): these pathways all contribute
to muscle protein wasting and apoptosis of skeletal muscle.29,30 Vitamin D is thought to
contribute to skeletal muscle maintenance, and the relative deficiency associated with
CKD is considered part of the mechanism for sarcopenia in this population.30 In fact,
supplementation with vitamin D in patients on hemodialysis has been demonstrated to
lead to increased thigh muscle cross-sectional area on MRI compared to controls.31
Additionally, the hypogonadal state of CKD further diminishes skeletal muscle mass
through the loss of testosterone’s anabolic influence. Testosterone enhances/preserves
muscle mass via stimulation of muscle protein synthesis, myoblast differentiation,
suppression of myostatin, induction of IGF-1 messenger RNA (mRNA), and supports the
regenerative muscle stem cells (satellite cells).32 In a randomized trial of dialysis patients,
testosterone supplementation with or without exercise significantly increased quadriceps
muscle cross-sectional area after 12 weeks, whereas control groups did not show any
change.33

While multifactorial in etiology, chronic systemic inflammation is thought to be a
significant contributory factor to the development of sarcopenia, and often stems from
chronic illness states, such as CKD.23,24,34In a cross-sectional study of patients on
hemodialysis for at least 1 year, measurement of muscle mass via CT scanning was
undertaken and the values were correlated with serum levels of IL-6 and CRP. Muscle
mass, as determined by thigh musculature cross-sectional area, was found to be
significantly associated with both inflammatory markers after controlling for dry weight
and creatinine kinetics.34 IL-6 has been reported as a modulator of acute-phase reactant
plasma proteins in vivo and has been implicated in cancer associated cachexia and muscle
breakdown; furthermore, in animal models of IL-6 transgenic mice, antibodies targeting
the IL-6 receptor lead to attenuation of proteolysis and muscle atrophy.34
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In addition, chronic low grade systemic inflammation has been suggested to predispose to
sarcopenia via activation of the ubiquitin-protease pathways, diminished anabolic effects
of hormones such as IGF-1, and subsequent ‘anabolic resistance’: a state of relative
resistance of muscle anabolism with a given macronutrient intake.24,29 The heightened
levels of oxidative stress associated with aging can induce immune system activation
thereby increasing levels of inflammatory cytokines and positively feedback on the
deleterious process of reactive oxygen species (ROS) creation in muscle, leading to
increased proteolysis, degeneration of neuromuscular junctions, and diminished degrees
of excitation-contraction coupling.24 The sum of these changes leads to loss of muscle
mass and impaired muscle function, both considered defining features of sarcopenia.

Oxidative stress is pervasive in states of advanced age, as well as several chronic diseases
that often contribute to CKD, in addition to CKD itself. The relative imbalance between
ROS and endogenous/exogenous antioxidants leads to a predisposition towards cellular
damage resulting in senescent cells.35 Aging cells are associated with the acquisition of a
senescence-associated secretory phenotype that involves the constitutive secretion of
chemokines, growth factors, and degradative enzymes.35 Diabetes mellitus can induce a
relative imbalance of ROS via persistent intracellular hyperglycemic conditions, and
chronic renal dysfunction can worsen ROS load via several mechanisms including
reduced levels of nitric oxide and persistent activation of polymorphonucleocytes.35
Even in the absence of advanced age, CKD and related conditions (i.e. diabetes) may
induce a sarcopenic state through numerous mechanisms.

Evidence for the influence of exogenous inflammation contributing to sarcopenia exists
as well. Hemodialysis, known to contribute to systemic inflammation through
blood/filtration system interactions, may also contribute to the induction of sarcopenia.
Takamoto and colleagues (2018) showed that in a cohort of patients undergoing renal
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transplant, the time spent on dialysis was significantly associated with sarcopenia. The
degree of sarcopenia was worse when time on dialysis was greater than the median time
of the cohort as compared to those with less than the median time on dialysis.36 The
mean±SD age of this cohort was 43±16 years, suggesting the drivers of differences in
sarcopenia for this population were likely related to CKD and dialysis itself without a
significant influence of age.

The complex nature of sarcopenia was further highlighted in a study of CKD patients
where sarcopenia, nutritional analysis, and inflammatory markers were assessed. When
compared to non-sarcopenic patients, those who had evidence of sarcopenia did not have
significantly different inflammatory marker profiles, nor did nutritional profiles
significantly differ.29 In this cohort, the mean age of sarcopenic and non-sarcopenic
patients was 79 and 80 years (respectively), suggesting that the influence of age related
sarcopenia and systemic inflammation may affect individuals differently depending on
inherent susceptibility.

Because the Fried phenotype of frailty focuses on physical frailty, which stems from
muscle function, the physiologic processes behind oxidative stress and subsequent
sarcopenia have significant overlap with frailty pathophysiology.35 Much like frailty’s
predictive value stems from the ability to quantify and qualify its severity, measurements
of sarcopenia require reproducible and objective measures to operationalize its use in
patient assessment. The prevalence of frailty is higher in sarcopenic compared to nonsarcopenic patients, even when age, nutritional status, and systemic inflammatory
markers were similar.29 While they are not interchangeable phenomena, frailty and
sarcopenia can stem from common pathophysiologic processes, conceptually represented
in the flow diagram below.
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Figure 7. Flow diagram illustrating the possible interplay between aging, sarcopenia
and frailty
Liguori, I., et al. (2018). "Oxidative stress, aging, and diseases." Clin Interv Aging 13: 757-772.

1.2.2.2

Measuring Sarcopenia

Functional testing, as the incipient component of sarcopenia assessment, may be done
using hand grip strength dynamometry as well as gait speed, among other validated
clinical tests.23 Muscle mass, a component of sarcopenia, may be quantified by one or
more other methods. Structural assessment can be obtained via imaging modalities,
including cross-sectional imaging using computed tomography (CT) or magnetic
resonance imaging (MRI), which allows measurement of specific muscle
groups/compartments, as well as dual energy x-ray absorptiometry (DEXA). Crosssectional imaging has typically been considered the gold standard for assessing muscle
mass, but the cost, availability, and potential safety issues with this type of imaging may
limit its utility for quantifying sarcopenia.37 An alternative, lower cost assessment
modality includes bioimpedance analysis (BIA). In a study of kidney transplant
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recipients, BIA estimations of skeletal muscle mass strongly correlated with psoas muscle
volume derived from CT measurements (r=0.761), and was highly correlative with
DEXA scanning (r=0.90).37

BIA is a method of body composition assessment utilizing bioimpedance, defined as the
vector sum of resistance (a measure inversely related to body water content) and
reactance of body tissue (a measure of tissue capacitance that varies depending on cell
membrane integrity, function, and composition) derived from transmitting low-amplitude
imperceptible current passed from the wrist to the ankle.38-40 Information derived from
BIA has been shown to be a reliable metric of body composition in the dialysis
population, predictive of clinical frailty, and may be prognostic for survival in
hemodialysis patients.41,42 Data obtained from BIA can provide an estimation of overall
health status utilizing the calculation of the bioimpedance phase angle (PhA). PhA is
thought to represent the relative health of human tissue at a cellular level, with decreased
reactance being reflective of intact, healthy cell membranes.37 The PhA is derived from
calculating the arc-tangent of the reactance divided by the resistance, multiplied by
180°/π.39 A significant correlation between PhA and survival has been observed in the
AIDS, lung cancer and critically ill populations.39 Furthermore, PhA has been suggested
to correlate with survival in those on hemodialysis as well.43 A visual explanation of the
relationship between reactance, resistance and phase angle is shown below.44
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Figure 8. Graph visualizing the relationship between bioimpedance values of
resistance, reactance, and phase angle
Davies, S. J. and A. Davenport (2014). "The role of bioimpedance and biomarkers in helping to aid clinical
decision-making of volume assessments in dialysis patients." Kidney Int 86(3): 489-496.

Support for using BIA-derived measures of muscle mass in kidney transplant recipients
comes from reports validating this metric. In a cross-sectional study by Ozkayar and
colleagues (2014) of 166 kidney transplant recipients, sarcopenia prevalence was
assessed using hand grip strength and fat free mass determined by BIA. Overall,
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sarcopenia was evident in 20% of the transplant recipient population, with a mean age of
44 in the sarcopenic group and 36 in the non-sarcopenic group.25 BIA measurement has
also been used as a tool to derive absolute values of skeletal muscle mass. Through
multiple regression analysis of BIA parameters and patient demographics, Janssen and
colleagues (2000) derived an equation to predict whole body skeletal muscle mass as
follows:

Skeletal muscle mass (kg) = [(Height2/R x 0.401) + (gender x 3.825) + (age x -0.071)] + 5.102

where height is measured in centimeters, the gender value is 1 for male and 0 for female,
and R is the measured resistance from BIA.45 This formula was created and validated in
a population made of up of Canadian and American volunteers, initially in patients of
Caucasian ethnicity and subsequently cross-validated in Hispanic, African-American, and
Asian subjects, and showed high correlation with a reference measurement of total
skeletal muscle mass derived from whole body MRI:
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Figure 9. Graph demonstrating the correlation between bioimpedance-derived
muscle mass and whole body MRI-derived muscle mass
Janssen, I., et al. (2000). "Estimation of skeletal muscle mass by bioelectrical impedance analysis." J Appl Physiol
(1985) 89(2): 465-471.

Healthy volunteers aged 18-86 years old with BMIs ranging from 16-48 kg/m2 comprised
the reference population for this equation.45 This estimating equation has been applied in
other settings to estimate skeletal muscle mass, and has been used in a large population
study. The NHANES III study captured BIA measurements in participants, and this data
has been used to show that BIA-derived skeletal muscle mass, expressed as a skeletal
muscle index (SMI = [muscle mass in kg/total body weight in kg] x 100%), can be used
to quantify sarcopenia in the general population and correlates with degree of functional
impairment.46 In this study by Janssen et al (2002), NHANES III participants aged 18-39
comprised the referent population, and those in the older age groups (39+) were stratified
by SMI, and those between 1 and 2 standard deviations below the referent population
were deemed moderately sarcopenic, while those greater than 2 standard deviations
below were severely sarcopenic. The results from this report provide population
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normative data for a North American population.46 An alternatively derived SMI,
normalizing muscle mass to height squared (kg/m2), has also been reported in older
populations and used to derive cut-off points that increase risk of physical disability.47
Unfortunately, these reports do not include data on patients with CKD or ESRD/dialysis,
and thus these estimating equations have not been validated in the renal failure
population.48 However, population normative data of BIA parameters (tissue resistance,
etc.) in the hemodialysis population has been published, therefore derivation of
population norms of skeletal muscle mass/SMI could be calculated and explored as a
reference for assessment of the dialysis-dependent population.38

1.2.2.2.1

Quadriceps Muscle Layer Thickness as a Possible
Measure of Sarcopenia

The relative access to body composition metrics, such as DEXA or BIA, may be limited
in some clinical settings. Alternative point of care assessments for muscle
mass/sarcopenia may be of use to clinicians in patient populations where sarcopenia is
prognostic or impact clinical decision making. While whole body assessment of skeletal
muscle mass may represent the only true quantification of this measurement, surrogate
measurements of regional muscle groups can be representative of whole body muscle
mass. In a study of whole body muscle mass with MRI, variations in the relative
distribution of muscle were observed and quantified, with pertinent findings displayed
below.49
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Figure 10. Graph showing the relative distribution of MRI-derived muscle mass
throughout the body
Lee, S. J., et al. (2004). "Relation between whole-body and regional measures of human skeletal muscle."
Am J Clin Nutr 80(5): 1215-1221.

Overall, the cross-sectional area of the thigh musculature represented the highest
correlation with whole-body muscle mass with R2=0.77 and 0.79 for males and females,
respectively.49 Assessment of thigh musculature represents an accessible means for
estimation of whole body skeletal muscle mass.

With the relative availability of bedside/point-of-care ultrasound in most clinical settings,
application of this technology as an assessment tool for muscle mass has been proposed
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in both healthy and ill populations.50-53 Bedside ultrasound measurement of muscle mass
has largely focused on the lower extremity, specifically the anterior thigh compartment.

Anterior thigh muscle can be assessed using point-of-care ultrasound by measuring
thickness or cross-sectional area of one or more individual muscles. In healthy older
aged females, anterior thigh muscle thickness was higher in those who participated in
recreational golfing as compared to sedentary controls.53 Additionally, the muscle
thickness of the anterior thigh compartment of healthy young male volunteers
significantly increased after 12 weeks of lower body resistance training, and the increases
in muscle thickness were found to correlate with changes in anatomic cross-sectional area
as well as MRI-derived volume of the vastus lateralis muscle.52 These small reports
suggest that ultrasound measurement of thigh musculature may be able to capture
meaningful variation in muscle mass within and between subjects, creating a rationale for
its use as a potential index of sarcopenia and/or frailty.

Assessment of the quadriceps muscle layer thickness (QMLT) has demonstrated
predictive value in the general elderly hospitalized population in terms of re-admission,
death, and functional decline.51 In a prospective cohort study of 100 patients aged 65 or
greater admitted to hospital for various medical conditions, Guerreiro and colleagues
(2017) demonstrated that QMLT was associated with the co-primary endpoint of rehospitalization or death at 3 months post discharge (RR = 1.24). This relationship was
also observed in a bedridden subgroup of the cohort (RR = 1.34). QMLT also correlated
with functional testing as well, including gait speed, timed-up-and-go test and handgrip
strength.51

QMLT measurements have also demonstrated concordance with other measurements of
skeletal muscle mass. Berger and colleagues (2015) showed that in healthy community
dwelling individuals, QMLT values correlated with lower limb fat free mass (r = 0.74), as
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well as total fat free mass derived from DEXA analysis (r = 0.71).50 Paris et al (2017)
reported on a prospective multicentre study validating bedside derived QMLT values in
critically ill populations. This group found that QMLT values moderately correlated with
absolute abdominal muscle cross-sectional area (at the L3 level) derived from CTscanning, with an r = 0.45.54 The strength of this relationship was largely driven by the
younger male cohort in their population. However, on multivariate regression analysis
QMLT alone demonstrated a concordance index of 0.67 in predicting low muscle mass
on CT, and this value improved to 0.77 when considered along with other covariates,
including age, BMI, gender, type of ICU admission, and co-morbidity index.54 QMLT
may fall short of predicting absolute muscle mass in isolation, but could represent a tool
to help stratify patients by category of total CT-derived muscle mass.

The potential application of QMLT measurement to the renal failure population requires
consideration of population specific variables, such as the impact of fluid shifts on
muscle thickness measurements. Sabatino and colleagues (2017) assessed the reliability
of QMLT measurement using bedside ultrasound in the critically ill population with
severe acute kidney injury requiring dialysis. In their cross-sectional observational study,
when QMLT measurements were compared pre- and post-dialysis, values did not
significantly differ. This was regardless of whether conventional 4-hour dialysis or
sustained low-efficiency dialysis (6-12 hours) was used, nor did degree of weight change
after dialysis impact QMLT measurements.55 While this population represents acute
dialysis as opposed to a chronically dialysis-dependent population, fluid shifts were
significant (range of -0.5 to -3.0kg of fluid removed across dialysis sessions)55, these
results provide reassurance that a patient’s fluid status likely does not acutely influence
QMLT measurements.

Given that bedside ultrasound of the QMLT depends upon a human operator to generate
and interpret the images, the validity of this measurement requires documentation prior to
its implementation. Reassuringly, the intraobserver variability and interobserver
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variability both showed excellent agreement in a cohort study by Guerreiro et al (2017)51,
as well as other studies of similar design.56 Formal study to validate this method of
muscle assessment in critically ill populations further supports its validity. Hadda et al
(2017) sought to quantify the intra- and interobserver reliability of the QMLT assessed by
ultrasound in the pneumosepsis population.57 Measurements were obtained from the right
thigh in the supine position with knee extended at the level of the midpoint between the
greater trochanter and lateral joint line of the knee in the sagittal plane, with minimal
pressure applied to the anterior thigh compartment. QMLT measures involved the muscle
tissue just deep to the fascia of the rectus femoris muscle down to the level of just
superficial to the periosteum of the femur (includes the vastus intermedius muscle). Two
observers independently completed measurements of all participants. The intra-class
correlation (ICC) of the intraobserver variability was excellent with values of 0.925 for
one examiner and 0.835 for the second; these ICC values suggest almost perfect
agreement. Interobserver variability produced an ICC of 0.992, and the mean difference
between measurements was -0.082 cm, well within the limits of agreement on BlandAltman analysis.57 The reliability of US derived QMLT in the critically ill population
has been replicated by other groups. Pardo and colleagues (2018) evaluated QMLT in a
population of patients admitted to a surgical critical care unit, obtaining measurements
from the two-thirds distance point between the ASIS and upper patella, as well as the
mid-point between these landmarks, and quantified changes in QMLT over time in the
ICU, as well as intra- and interobserver variability. The ICC of intraobserver variability
was 0.74 while the ICC of interobserver variability was 0.76, representing moderate
agreement.58 In contradistinction to the report by Hadda et al (2017), these authors
performed QMLT measurement with maximal compression of the anterior thigh
compartment to compress the muscle to account for potential underestimation of muscle
thickness due to tissue edema. The degree of compression was targeted to be maximal
pressure without inflicting pain. The degree to which subcutaneous tissue may be
compressible likely varies between ages and genders54 which may have led to variability
in compressive force applied within and between assessors. As well, pain infliction may
be subjective and vary depending on patients’ state of consciousness. Thus, the lower
ICC values could stem from this alternative approach to QMLT measurement. On
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balance, Paris and colleagues (2016) in a multicentre prospective study of critically ill
patients assessed QMLT with the maximal compression method, and returned higher ICC
values, with intrarater reliability ICC = 0.98 and interrelater reliability ICC = 0.94.54
Other reports have demonstrated excellent intra- and interobserver agreement with a
minimal compression technique.50,55,59 With ICC values of reliability ranging from 0.74
to 0.99 among both minimal and maximal thigh compression methods, it appears bedside
assessment of QMLT with either technique using ultrasound is likely reliable and
reproducible.

Further confidence in the QMLT measurement by bedside ultrasound was presented by
Tillquist and colleagues (2014). In their prospective, multicentre international
observational study of ICU patients, intra- and interobserver variability between
physicians with significant point of care ultrasound experience and trainees that consisted
of dieticians, nurses, physiotherapists, coordinators, and technicians were compared;
most trainees had no ultrasound experience. Instruction to trainees was provided in the
form of a manual, instructional video, and hands-on teaching. Within operator
measurements produced an ICC of 0.98 across 12 study locations, and across 78 pairs of
trainer-trainee comparisons the ICC was 0.95, with the mean difference in measurements
not significantly different.59 Bedside US derived QMLT measurements across novice
and expert examiners create reproducible results, and appears to have validity in the
critically ill and dialysis dependent populations.

The application of QMLT to the chronic hemodialysis dependent population (ESRD-HD)
has been reported and supports its use as a potential metric of sarcopenia. Sabatino and
colleagues (2019) in a cross-sectional prospective observational study evaluated QMLT
measurements of HD patients in comparison to healthy and age-matched hospitalized
controls. These authors found that QMLT values were significantly lower in the ESRDHD population.60 Of note, their QMLT assessment involved minimal pressure
application of the ultrasound probe perpendicular to the anterior thigh. Importantly, they
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also found measurements performed pre- and post-dialysis were not significantly
different regardless of degree of fluid shift, consistent with another report on QMLT in
the setting of AKI.55 QMLT values were moderately correlated with several metrics of
protein energy wasting (a contributor to sarcopenia), including BMI (r = 0.36) and serum
albumin (r = 0.27). This report found a stronger correlation between QMLT and the
Malnutrition Inflammation Score (MIS), a validated tool to evaluate nutrition and risk of
mortality in the renal failure population, where a score of 6 represents the population
mean (r = -0.47).60,61 Patients with MIS scores of ≥ 6 had significantly lower QMLT
values compared to those having a score of < 6.60 No reference standard of skeletal
muscle mass was available for correlating QMLT (i.e. DEXA scans, CT scans), however
there was a clear and consistent relationship between QMLT values and a validated
measure of protein energy wasting, which may be considered as a surrogate for a
sarcopenic state, and possibly frailty, in the ESRD-HD population. QMLT therefore
could represent as a practical tool for bedside estimation of skeletal muscle mass and
sarcopenia/frailty, both quantitatively and qualitatively.

1.3 Thesis Objectives
This thesis addresses 3 main objectives by way of an integrated-article format. The
overarching theme is the influence of frailty and sarcopenia on kidney transplant
outcomes. The interrelated nature of sarcopenia and frailty, as well as the impact both
may have on transplant outcomes, makes studying a convenient and clinically accessible
surrogate measure attractive. The initial focus of this project was to assess the QMLT, a
relatively novel tool, as it relates to frailty and sarcopenia. It was thought that the QMLT
could represent a single-step, convenient method for case-detection of frailty/sarcopenia
that could improve access to this form of testing in the clinical setting.

First, the QMLT was used as a potential surrogate of frailty/sarcopenia and its impact on
clinical outcomes. The relationship between QMLT and length of stay in hospital after
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renal transplant was assessed. The QMLT values delineated two cohorts for comparison
of length of stay and other related outcomes.

As a follow up, the ability of the QMLT to specifically predict sarcopenia was assessed
by defining sarcopenic patients using EWGSOP2 criteria and comparing their attributes
to their non-sarcopenic counterparts. This comparison allowed for assessment of the
QMLT as a surrogate for identifying sarcopenic patients.

Finally, the agreement and concordance between several different metrics of sarcopenia
were examined, including bioimpedance derived-muscle mass, clinical metrics of muscle
function, CT measures of muscle mass, as well as QMLT. It was thought these
observations will contribute to better appreciating the role each of these modalities might
play in assessing sarcopenia in renal transplant recipients.

The current literature is essentially devoid of reports examining those receiving a kidney
in concert with a pancreas (simultaneous pancreas-kidney transplant) in the setting of
ESRD secondary to type 1 diabetes. There has been suggestion that type 1 diabetes may
accelerate loss of muscle mass, and a single report has documented a possibly higher rate
of complications in sarcopenic patients undergoing pancreas transplant either with or
without a concurrent kidney transpant.63 We therefore opted to include this population of
transplant recipients in this project to add to this nascent area of the literature.
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Chapter 2

2

The Impact of Quadriceps Muscle Layer Thickness on
Length of Stay in Those Awaiting Renal Transplant

2.1 Introduction
Frailty has emerged as a relevant prognostic tool in the kidney transplant population.1 As
a construct derived from the geriatrics literature, frailty has come to be recognized as an
accumulation of deficits leading to a reduced ability to withstand physiologic stress, in
both the general population and those undergoing kidney transplant.2,3 Those who are
frail have been found to have longer length of stay (LOS) in hospital after transplant.3
Frailty has been most commonly assessed in this population using the Physical Frailty
Phenotype, and the scoring reflects measures of muscle function, mass, and activity.2

The quadriceps muscle layer thickness (QMLT) represents an emerging form of bedside
assessment of muscle mass of the lower thigh, with validation in the critically ill,
community dwelling elderly, and healthy populations.4-7 The QMLT has the potential to
serve as a relatively inexpensive screening tool for identifying patients who may be frail.

At present, the QMLT has not been studied in patients undergoing kidney transplant. The
relatively low cost and wide availability of point of care ultrasound makes this modality
an attractive tool to explore to identify patients at risk or poor outcomes. LOS is a metric
of patient outcomes that is associated with reduced global healthcare costs, and is an
objective marker of how quickly patients recover after surgery.
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2.2 Purpose and Hypothesis
The purpose of this study was to assess whether QMLT values obtained at the time of
transplant in those with end stage renal disease are predictive of the total length of stay in
hospital following transplant.

It was hypothesized that those patients pending a renal transplant with lower measures of
QMLT would have longer lengths of stay following transplant, as well as higher rates of
infection and rejection in the early post-transplant period.

2.3 Methods
This is a prospective observational cohort study performed at London Health Sciences
Centre University Hospital in Ontario, Canada. Patient recruitment occurred from March
1, 2019 until Jan 1, 2020, where all patients presenting for a kidney or combined kidneypancreas transplant were invited to participate. Patients were excluded if they were under
18 years of age, receiving a concurrent liver or heart transplant, or refused to participate.
Upon recruitment, patients provided written informed consent to participate, at which
point data collection occurred which included, age, gender, height, weight, BMI, type of
donor (donation after brain death [DBD], donation after circulatory death [DCD], living
donor [LD]), panel reactive antibody (PRA%), Physical Frailty Phenotype scores, and
quadriceps muscle layer thickness (QMLT).

The Physical Frailty Phenotype was assessed using the criteria set out by Fried et al
(2001). Components of the Frailty Phenotype included patient reported unintentional
weight loss of >10% over the last year, self-reported exhaustion, weekly physical
activity, hand grip strength assessed by a Jamar dynamometer, and time to walk 15 feet at
one’s usual pace. Gender and BMI stratified cut-offs used in clinical practice were
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utilized for assessing the presence or absence of each frailty component. A composite
score of >2 indicated the presence of frailty. (Appendix 1)

QMLT is a measurement of the anterior thigh compartment musculature comprising the
rectus femoris muscle and the vastus intermedius muscle. Point of care ultrasound (BK
technology) was used to quantify this value. With the patient in the supine position and
feet pointed forward, a tape measure was used to measure the distance from the anterior
superior iliac spine to the superior border of the patella, and the halfway point was
marked with indelible ink on the anterior aspect of the thigh in the midline of the lower
limb. A curvilinear probe set to 6Hz and with ample ultrasound jelly assessed this point
of the thigh musculature. The depth was adjusted so the femur and superficial adipose
were visible at the bottom and top of the ultrasound image, respectively. Light pressure
was applied to observe tissue dispersion to confirm the discrimination of the visible
layers as muscle versus adipose. Pressure was released to the point of minimal pressure
from the probe, allowing contact with the probe to the skin with no external compression
applied. The image was then frozen, and electronic calipers measured the vertical
distance from the inner layer of the rectus femoris muscle fascia to the level of the femur
periosteum to obtain the QMLT. This measurement was repeated for a total of three
measurements and then repeated on the contralateral thigh. The mean value of the six
measurements obtained comprised the patient’s QMLT value. An example of the QMLT
being measured is depicted in Figure 11.
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Figure 11. Representative ultrasound image capturing the quadriceps muscle layer
thickness and electronic calipers

Patients were then followed prospectively for outcome assessment. The primary outcome
of interest was the length of stay in hospital following transplant, assessed both as a
continuous variable and as a nominal variable of greater than/equal to or less than 14
days. Secondary outcomes of interest included the occurrence of infectious complication,
rejection, and renal function at 1 month post-transplant measured using serum creatinine
level; infection and rejection assessment was limited to the first month after transplant.
Infection was deemed present if the following criteria were met: culture evidence of
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microbial infection with clinical symptoms and/or treatment with antimicrobials, OR
radiographic evidence of infection with clinical symptoms and/or treatment with
antimicrobials. An infection was not considered present if a patient was treated with a
course of antibiotics for prophylaxis or for pre-emptive treatment of a possible donorderived pathogen. Rejection was documented if there was a biopsy post-transplant
documenting graft rejection in the presence of graft dysfunction and treatment provided
directed at rejection. Graft function was categorized as delayed if dialysis was required
within 7 days of transplant, and was otherwise deemed immediate.

Statistical analysis was carried out using SPSS v 26.0. Demographic data was
summarized using descriptive statistics. QMLT values were organized by percentile. A
cut-off of the 20th percentile was used to divide patients into two categories of QMLT
(low and higher). Kolmogorov-Smirnov testing assessed for assumptions of normality
and the continuous outcomes compared using a two-sided t-test or Mann-Whitney U test
where appropriate. Chi square analysis and Fisher exact testing for nominal variables
were performed. Multivariable regression assessed the predictive impact of QMLT on
LOS while controlling for relevant variables. Alpha was set at 0.05 and all analyses were
two-tailed. An a priori sample size of 74 was chosen to allow for assessing the
difference in LOS using unpaired t-test using G*Power 3.1 software, with an effect size
of 0.67 based on local data on LOS (mean LOS = 9.0 days, S.D. = 4.5, a 3 day difference
in LOS being deemed clinically significant). For the purposes of multivariable regression
to be performed on 5 variables of interest, using the guide of 15 patients per variable of
interest, a sample size of at least 75 was sought. We therefore aimed to accrue up to 88
patients to allow for a 10-20% rate of attrition. Patients lost to follow up due to early
structural graft loss or death were not included in the assessment of our stated outcomes.
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2.4 Results
During the study accrual period a total of 85 patients provided consent to participate, with
79 patients providing complete data for analysis. Baseline data is presented in Table 1.
The cut-off value to define two QMLT groups at the 20th percentile was determined to be
2.63cm. The range of QMLT was 1.09-6.50cm.

A comparison of the outcome measures based on QMLT group is outlined in Table 2.
Kolmogorov-Smirnov testing determined that LOS, PRA%, and creatinine at 1 month
violated assumptions of normality and were therefore compared non-parametrically using
Mann-Whitney U test. All other continuous variable satisfied assumptions of normality.

The LOS over 14 days was significantly higher in those with lower QMLT. Additionally,
LOS was significantly longer in the low QMLT group (12.0 vs 8.0 days, p = 0.04). The
difference in distribution for the type of donor (living, DCD, DBD) approached
significance (p = 0.052), in favor of fewer living donors in the low QMLT group. The
remaining demographic variables did not differ between the groups, nor did the
secondary outcomes of rates of infection, rejection, or creatinine at one month. Notably,
the breakdown of frailty phenotype scores did not differ between the groups (Table 2).
Given that there was an apparent discrepancy in the rates of living donors between the
low and high QMLT groups (7% vs 40%), we repeated the comparisons excluding living
donor recipients. The results for this analysis are displayed in Table 3. When LOS was
categorized into >14d or ≤14d, the difference was preserved (23% vs 0%, p = 0.01). The
difference in mean LOS was no longer significant after exclusion of living donor
recipients (12.0 vs 9.0 days, p = 0.22). This subsequent analysis carried a power
calculated post hoc of 36%.
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Multivariable analysis to assess for contributors of LOS was performed with entry of 5
variables of interest: QMLT, Age, Graft function (delayed vs immediate), Frailty
phenotype score, and Donor Type. Because LOS violated the assumptions of normal
distribution, LOS was log-transformed for multivariable regression. Overall the model
constructed was significantly predictive of LOS, with R2 = 0.33, F(5,74) = 8.89, p<0.001.
The factors of deceased donor and presence of DGF conferred significant regression
weight for greater LOS prediction (Table 4).
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Table 1. Demographic and Outcome Data for Cohort of ESRD patients Undergoing
Kidney Transplant
Mean

S.D./%

N

79

Age

49.9

14.4

Gender (%M)

51

65%

BMI

28.7

5.5

QMLT (cm)

3.66

1.14

20%ile QMLT

2.63

LOS (days)

8.7

4.2

Infection (N)

19

24%

Rejection (N)

5

6%

Frailty score (median)

1

0

22

28%

1

28

35%

2

12

15%

3

8

10%

4

5

6%

Unknown

4

5%

DGF

17

22%

LD

27

34%

DBD

29

37%

DCD

23

29%

SCD

68

86%

Donor type

45

ECD

11

14%

Cr 1 month

138

91

%PRA

25%

38%

Transplant (KTx/SPK)
(K(KTx/SPK)

73/6

92%/8%

* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor;
DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous
pancreas/kidney transplant; PRA = Panel Reactive Antibody; Cr = Creatinine; QMLT =
Quadriceps Muscle Layer Thickness
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Table 2. Outcome Data of ESRD Kidney Transplant Recipients Between Low and
Higher QMLT Cohorts
<20%ile

>20%ile

N

QMLT
14

QMLT
65

Age (mean)

52.8 (15.3)

49.2 (14.1)

0.4

Gender (%M)

11 (79%)

40 (62%)

0.36

LOS

12.0 (7.4)

8.0 (2.8)

0.04

LOS > 14d

3 (21%)

2 (3%)

0.04

Infection

2(14%)

17(26%)

0.5

Rejection

2 (14%)

3 (5%)

0.31

DGF

29%

20%

0.65

BMI

28.0 (5.8)

28.9 (5.6)

0.63

LD

1 (7%)

26 (40%)

0.05

DBD

8 (57%)

21 (32%)

DCD

5 (36%)

18 (28%)

SCD

11 (79%)

57 (88%)

ECD

3 (21%)

8 (12%)

Frailty score

p value

0.3

0.7

0

3 (21%)

19 (31%)

1

6 (43%)

22 (36%)

2

3 (21%)

9 (15%)

3

2 (14%)

6 (10%)

4

0 (0%)

5 (8%)

Cr 1 months

153 (98)

135 (90)

0.81
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PRA

34 (44)

23 (35)

QMLT

2.07 (0.44)

4.04 (0.90)

KTx/SPK

12 / 2

61 / 4

0.18

* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor;
DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous
pancreas/kidney transplant; PRA = Panel Reactive Antibody; Cr = Creatinine;
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Table 3. Outcome Data of Low and Higher QMLT Cohorts after Censoring of
Living Donor Transplant Recipients
<20%ile

>20%ile

N

QMLT
13

QMLT
39

Age (mean)

54.8 (13.7)

49.9 (15.4)

0.5

Gender (%M)

10 (77%)

22 (56%)

0.324

LOS

12.0 (7.4)

9.0 (2.6)

0.22

LOS > 14d

3 (23%)

0 (0%)

0.01

Infection

2 (15%)

11 (28%)

0.48

Rejection

2(15%)

2 (5%)

0.26

DGF

31%

33%

0.68

BMI

28.3 (4.9)

29.5 (5.3)

0.31

LD

0 (0%)

0 (0%)

0.63

DBD

8 (62%)

21 (54%)

DCD

5 (39%)

18 (46%)

SCD

10 (77%)

31 (80%)

ECD

3 (23%)

8 (21%)

Frailty score

p value

1.0

0.77

0

3 (23%)

11 (30%)

1

5 (39%)

16 (43%)

2

3 (23%)

7 (19%)

3

2 (15%)

2 (5%)

4

0 (0%)

1 (3%)

Cr 1 month

155 (102)

146 (112)

0.89
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PRA

37% (45%)

29% (38%)

QMLT

2.05 (0.45)

4.00 (0.92)

0.4

*All data are presented as N(%) or Mean (S.D.)
**DBD = Donation after Brain Death; DCD = Donation after Circulatory Death; SCD =
Standard Criteria Donor; ECD = Extended Criteria Donor; DGF = Delayed Graft
Function; KTx = Kidney transplant; SPK = simultaneous pancreas/kidney transplant;
PRA = Panel Reactive Antibody; Cr = Creatinine;
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Table 4. Multivariable Regression Data for Length of Stay (log transformed)
Unstandardized

Standardized

Coefficients

Coefficients

B

Std. Error

(Constant)

1.742

0.219

QMLT

-0.02

0.035

-0.056

Graft function

0.258

0.08

Age

0.004

Living vs Deceased
Frail vs Not frail

95% Confidence Interval
t

Sig.

for B

Beta

Lower Bound

Upper Bound

0

1.305

2.178

0.95

0.566

-0.09

0.05

0.327

1.39

0.002

0.097

0.418

0.003

0.142

1.15

0.153

-0.001

0.009

0.25

0.087

0.305

1.36

0.005

0.077

0.423

-0.104

0.09

-0.111

0.89

0.253

-0.283

0.076

*Graft function refers to delayed graft function compared to immediate graft function
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2.5 Discussion
In this prospective cohort study of kidney and kidney-pancreas transplant recipients, the
QMLT was used as a novel assessment tool for identifying patients at risk for prolonged
length of stay in hospital. Overall, those with a low QMLT, defined as measuring below
the 20%ile of the cohort, demonstrated a significantly greater proportion with LOS over
14 days (21% vs 3%, p = 0.04), as well as longer mean length of stay in hospital (12.0 vs
8.0 days, p = 0.04).

This difference in LOS may be due to QMLT being representative of frailty. Frailty
prevalence was 16% overall (defined as a Frailty Phenotype score > 2). This is lower than
other recent reports of frailty incidence in those undergoing kidney transplant, suggesting
our population may be more robust than other series of kidney transplant recipients
examined for frailty.8 The components of the Frailty Phenotype include weight loss, slow
walking speed, exhaustion, reduced activity, low hand grip strength.2 Given these
measures are derivatives of skeletal muscle use, it stands to reason that frailty may be
coexistent with significant loss of skeletal muscle mass and thus could be reflected in the
observed quadriceps muscle layer thickness if enough mass was lost overall. In
community-dwelling elderly and critically ill populations, QMLT has been shown to
moderately correlate with lower limb and total fat-free mass derived from whole body
assessments.6,9

Frailty has been associated with longer length of stay after transplant. McAdamsDeMarco (2017) utilized SRTR data linked to local institutional data to create a hybrid
registry-augmented regression model to precisely estimate the impact of several donor
and recipient factors with the ability to estimate the influence of frailty.3 Through this
analysis, frailty conferred a 1.6-fold higher risk of being hospitalized greater than 2
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weeks after transplant. We also observed that lower QMLT was associated with a higher
risk of LOS > 14 days. We did not observe an association between Frailty Phenotype
score and LOS on either pooled analysis or on multivariable regression in our cohort.
This may relate to the lower prevalence of frailty in our cohort which may limit the
ability to adequately assess this relationship. With a greater number of patients powered
to test the relationship between QMLT and Frailty phenotype, a clearer association may
emerge.

The rates of the secondary outcomes of infection, rejection, and creatinine at 1 month
were not significantly different between low and high QMLT groups. It was
hypothesized that QMLT may represent a surrogate marker of frailty, thus representing a
state of systemic inflammation and inability to withstand extra stressors.2,10 Given the
known derangements of inflammatory markers such as IL-6 in frail populations, we
hypothesized greater rates of infection and rejection.11 As a result, rates of the clinically
relevant insults of infection and rejection were assessed according to QMLT group.
QMLT in our cohort was not a robust discriminator of these events. There was a
relatively low event rate of rejection overall (6%), thus a larger sample size may help
better define the influence of QMLT on rejection. Rates of readmission in larger series,
often due to infection or rejection events, after kidney transplant have shown differential
rates between the frail and non-frail in other reports.12 The attendant immunosuppression
of all transplant recipients may suppress the influence of frailty on the ability to avoid
clinical infection in smaller sample sizes, thus a larger study may be able to better clarify
the prognostic ability of QMLT for these events.

A significant driver of increased LOS in our cohort appears to be the type of donor and
the presence of DGF. The influence of donor type is first evident by the different rates of
donor types between the low and high QMLT groups (Table 2). When LD’s were
censored, the significance of the difference in mean length of stay was lost (12.0 vs 9.0
days, p = 0.22), but the proportion of recipients remaining in hospital beyond 14d
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remained significantly higher in the low QMLT group. Eliminating LD’s significantly
reduced the numbers in each group and this analysis was subsequently under powered to
detect a difference in mean LOS. It has been shown in other reports that frailty
significantly increases the risk of LOS beyond 14d after kidney transplant.3 The similar
influence of QMLT supports this measure as being potentially indicative of frailty.

The significant impact of donor type on LOS is further clarified by a multivariable
regression analysis model using age, graft function, type of donor, frailty status, and
QMLT as predictors of LOS. Although both donor type and graft function significantly
contributed to regression estimates, this model accounts for only 33% of the residual
variation, confirming other factors not included in this model have appreciable influence
on LOS. It may be that with greater numbers, QMLT may demonstrate a clearer influence
on LOS, and our sample size was not adequate for logistic regression to assess the odds
for LOS >14d.

Given that DGF involves dialysis within the first week of transplant, a longer stay in
hospital seems natural while waiting to define the progression and trajectory of renal
function. DGF has been associated with longer LOS after renal transplant in other series
as well.3 Even in the absence of DGF, deceased donor transplants may display higher
rates of “slow graft function”, or a less than ideal improvement in renal function without
requiring dialysis. This logically leads to longer stays in hospital and has also been
demonstrated in larger series.3

QMLT is a direct measure of one muscle compartment. Although it was predictive of
prolonged LOS, it may not be sensitive enough to adequately reflect clinical frailty.
Rather, QMLT may more clearly represent a measure of sarcopenia, or pathologic loss of
muscle mass. Sarcopenia is likely a part of the underlying pathophysiology of frailty.10,11
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The current study was not structured to assess the relationship between QMLT and
sarcopenia, but this concept is explored in subsequent chapters.

The discrepant rates of donor types in the low and high QMLT groups may also
underscore an unappreciated bias in selecting patients for transplant. It is possible that
QMLT may be correlated to some other factor not captured within this study that reduces
a patient’s likelihood of having or being approved for a living donor transplant. This is
another area deserving of further study.

This prospective cohort study represents one of the first to examine QMLT in the renal
transplant population, with preliminary suggestion that QMLT may relate to LOS in
hospital. There are significant limitations to this study. The current study was powered to
detect meaningful differences in LOS and allow for multivariable regression, however the
relatively small sample size prevented meaningful subgroup analysis. Further, QMLT
provides a metric of muscle size, but it does not measure muscle quality. Fat infiltration
of the muscle may be evident subjectively during US assessment of the QMLT by
making the muscle appear brighter, but in our current model of QMLT assessment,
qualitative assessment of muscle is not incorporated. Future studies investigating the
utility of QMLT should consider integrating muscle quality into QMLT assessment.
Lastly QMLT measures one compartment of the appendicular musculature, and further
research is needed to validate this measurement as a marker of sarcopenia in this
population.
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Chapter 3

3

The Relationship Between Quadriceps Muscle Layer
Thickness and Sarcopenia in the End Stage Renal
Disease Population

3.1 Introduction
Sarcopenia and frailty are two related but distinct conditions affecting the elderly and the
renal failure population of all ages.1 Reports have shown that age alone is not enough to
adequately discriminate the presence of these conditions, especially in those with end
stage renal disease (ESRD).2 The importance of sarcopenia and frailty in the ESRD
population is gaining appreciation, with longer lengths of stay, higher re-admission rates,
and worse mortality after kidney transplantation.3,4

The quadriceps muscle layer thickness (QMLT) represents an emerging form of bedside
assessment of muscle mass of the lower thigh, with validation in the critically ill,
community dwelling elderly, and healthy populations.5-8 The QMLT has the potential to
serve as a relatively inexpensive screening tool for identifying patients at risk of low
muscle mass and potentially sarcopenia and frailty.

There is currently a lack of studies examining the utility of QMLT in the ESRD and renal
transplant population. Current consensus guidelines recommend sarcopenia be diagnosed
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based on functional assessment as well as total muscle mass assessment, the latter often
requiring specialized equipment.9 QMLT has the potential to serve as a tool to detect
cases of low muscle mass/frailty in this population.

3.2 Purpose and Hypothesis
The purpose of this study is to assess the relationship between QMLT in the ESRD
population presenting for transplant and the presence of sarcopenia and frailty.

It was hypothesized that the QMLT would be associated with measures of sarcopenia as
defined by the European Working Group on Sarcopenia in Older Persons (EWGSOP2)
criteria.

3.3 Methods
This is a prospective observational cohort study performed at London Health Sciences
Centre University Hospital in Ontario, Canada. Patient recruitment occurred from March
1, 2019 until Jan 1, 2020, where all patients presenting for a kidney or combined kidneypancreas transplant were invited to participate. Patients were excluded if they were under
18 years of age, receiving a concurrent liver or heart transplant, had an implanted
defibrillator, or refused to participate. Upon recruitment, patients provided written
informed consent to participate, at which point data collection occurred which included,
age, gender, BMI, type of donor (donation after brain death [DBD], donation after
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circulatory death [DCD], living donor [LD]), physical frailty phenotype scores (which
includes hand grip strength and walking speed), quadriceps muscle layer thickness
(QMLT), and bioimpedance analysis (BIA).

QMLT is a measurement of the anterior thigh compartment musculature comprising the
rectus femoris muscle and the vastus intermedius muscle. Point of care ultrasound (BK
technology) was used to quantify this value. With the patient in the supine position and
feet pointed forward, a tape measure was used to measure the distance from the anterior
superior iliac spine to the superior border of the patella, and the halfway point was
marked with indelible ink on the anterior aspect of the thigh in the midline of the lower
limb. A curvilinear probe set to 6Hz in B-mode and with ample ultrasound jelly assessed
this point of the thigh musculature. The image depth was adjusted so femur and
superficial adipose were visible at the bottom and top of the ultrasound image,
respectively. Light pressure was applied to observe tissue dispersion to confirm the
discrimination of the visible layers as muscle versus adipose. Pressure was released to the
point of minimal pressure from the probe, allowing contact with the probe to the skin
with no external compression applied. The image was then frozen, and electronic calipers
measured the vertical distance from the inner layer of the rectus femoris muscle fascia to
the level of the femur periosteum to obtain the QMLT. This measurement was repeated
for a total of three measurements and then repeated on the contralateral thigh. The mean
value of the six measurements obtained comprised the patient’s QMLT value.
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Biompedance analysis (BIA) was performed using a Biomarkers 1500 Body Scan
Analyzer (©Biodynamics Corporation), utilizing 50kHz current of 1mA. Patients were
assessed in the supine position with electrodes place on the dorsum of the right hand and
right foot. Output from the BIA included tissue resistance, reactance, and phase angle.
The raw values were used to compute total skeletal muscle mass according to the formula
by Janssen et al (2000), which takes into account patient age (years), height (cm) and
gender (male = 1) as well as BIA parameter Resistance (R):

Skeletal muscle mass (kg) = [(Height2/R x 0.401) + (gender x 3.825) + (age x -0.071)] + 5.102

Total skeletal muscle mass was indexed to the square of the patient’s height to derive the
skeletal muscle mass index (SMI). An SMI < 10.76kg/m2 for males and <6.7kg/m2 for
females defined low muscle mass, as per EWGSOP recommended cut-offs.10

Hand grip strength was measured using a Jamar dynamometer using the dominant hand
in a seated position with the elbow at 90°. Three measurements were taken with the
highest value constituting the hand grip strength. Walking speed was assessed by having
patients walk 15 feet timed with a stop watch. This was repeated once and the average
times were used to calculated the average walking speed (m/s).
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Sarcopenia was defined according the EWGSOP2 criteria.9 The incipient criteria for
sarcopenia was hand grip strength below 27kg for males and 16kg for females. If this
criterion was met, then the presence of either walking speed <0.8m/s (indicating poor
muscle performance), and/or the presence of low SMI (indicating low muscle mass)
defined a case of sarcopenia. Patients were then categorized as either sarcopenic or nonsarcopenic. Demographic data and mean QMLT values were recorded. KolmogorovSmirnov testing assessed for assumptions of normal distribution of data. Data was
compared between the groups using a two-tailed t-test or Mann-Whitney U test for
continuous data where appropriate, and Chi-square or Fisher exact testing for categorical
data with an alpha of 0.05. A receiver operator curve was constructed to identify the
performance of QMLT in predicting the presence of sarcopenia and SMI below genderstratified cut-offs as binary conditions.
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3.4 Results
A total of 79 patients met criteria for inclusion in the study and were analyzed for
demographic data and is shown in Table 5. The group was divided by gender to allow for
a stratified assessment of sarcopenia. Kolmogorov-Smirnov testing confirmed
satisfaction of normal distribution for all continuous variables except for hand grip
strength and this variable was thus analyzed non-parametrically.

Other than hand grip strength and skeletal muscle mass index (SMI), the male and female
subgroups did not differ in measured variables (Table 6). The incidence of low genderstratified hand grip strength, the primary criteria for determining sarcopenia, was similar
between the males and females (20% vs 21%, p =0.85). Males showed a higher incidence
of low SMI compared to females, but a similar proportion scored slow walking speed
(<0.8m/s). The incidence of sarcopenia was not significantly different between the
groups. QMLT measurements did not differ by gender.

When considering patients with complete data to assess QMLT, demographics and
presence of sarcopenia, 74 patients had complete data for analysis (Table 7). The mean
age of those with sarcopenia was significantly higher than those without (60.6 [12.5]yr vs
47.8[13.7]yr, respectively, p = 0.01). The mean QMLT value did not significantly differ
between those with or without sarcopenia (3.19 [0.90]cm vs 3.74[1.14]cm, respectively, p
= 0.17)
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The performance of QMLT as a screening tool for sarcopenia, low SMI, and frailty was
tested using receiver operator curve analysis (Figures 10, 11). The area under the curve
(AUC) for QMLT predicting the presence of sarcopenia was 0.64 with 95% CI of (0.470.82), p = 0.17. The AUC for QMLT detecting low SMI was 0.68 with 95% CI of (0.520.85), p = 0.04. Regarding frailty prediction, QMLT was not predictive of clinical frailty
with an AUC of 0.52 (95%CI 0.35-0.68) p = 0.85; QMLT was not predictive of either
low hand grip strength (AUC = 0.60 95%CI [0.44-0.76]) or slow walking speed (AUC =
0.54 95%CI [0.38-0.70]).
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Table 5. Demographic and Baseline Data for Entire Cohort
Values expressed as Mean (SD) or N (%)

N

79

Age

49.9 (14.3)

QMLT

3.66 (1.14)

QMLT <20%ile

14 (18%)

BMI

28.7 (5.5)

HGS

33.5 (13.2)

Male

51 (65%)

Sarcopenia

10 (13%)

Frail

17 (22%)

Donor
LD

27 (34%)

DBD

29 (37%)

DCD

23 (29%)

ECD

11 (14%)

KTx

73 (92%)

SPK

6 (8%)

Slow walk time

18%

Low SMI

24%

SMI kg/m^2

11.2 (2.6)

* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor;
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DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous
pancreas/kidney transplant; Cr = Creatinine; QMLT = Quadriceps Muscle Layer
Thickness

Table 6. Comparison of Demographic and Outcome Measures Between Male and
Female Recipients
Male

Female

N

48

26

Age

50.0 (14.0)

49.6 (15.3)

0.92

QMLT

3.63 (1.16)

3.71 (1.11)

0.76

QMLT <20%ile

11 (22%)

3 (11%)

0.23

BMI

29.2 (5.6)

27.9 (5.2)

0.28

HGS

38.7 (12.9)

23.9 (6.8)

<0.001

Sarcopenia

7 (15%)

3 (12%)

0.72

Frail

6 (12%)

7 (27%)

0.10

Donor

P - value

0.74

LD

19 (37%)

8 (29%)

DBD

18 (35%)

11 (39%)

DCD

14 (28%)

9 (32%)

ECD

5 (10%)

6 (21%)

0.14

KTx

48 (94%)

25 (89%)

0.66

SPK

3 (6%)

3 (11%)

Slow walk time

30 (64%)

12 (57%)

0.60

Low SMI

14 (32%)

1 (5%)

0.03
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SMI kg/m^2

12.0 (2.19)

9.26 (2.40)

<0.001

Low HGS

10 (20%)

6 (21%)

0.85

* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor;
DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous
pancreas/kidney transplant; Cr = Creatinine; QMLT = Quadriceps Muscle Layer
Thickness
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Table 7. Comparison of Sarcopenic and Non-Sarcopenic Groups
Sarcopenic

Non-Sarcopenic

N

10

64

Age

60.6 (12.5)

47.8 (13.7)

0.01

QMLT

3.19 (0.90)

3.74 (1.14)

0.17

BMI

28.5 (5.5)

31.6 (4.9)

0.11

Frail

3 (30%)

13 (20%)

0.44

QMLT<20%ile

3 (30%)

10 (16%)

0.36

QMLT = Quadriceps Muscle Layer Thickness

P-value

68

Figure 12. ROC assessing QMLT as a Predictor of Sarcopenia

Figure 13. ROC assessing QMLT as a predictor of low Skeletal Muscle Index
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3.5 Discussion
In this prospective cohort study of patients with ESRD presenting for kidney or combined
kidney-pancreas transplant, the QMLT measurement emerged as a poor predictor for the
presence of sarcopenia and frailty. However, the QMLT did demonstrate a significant
AUC for the prediction of low SMI as assessed from BIA estimates (AUC = 0.68, p =
0.04).

Sarcopenia was assessed according to the EWGSOP2 consensus on sarcopenia criteria
where low hand grip strength (stratified by gender) was the primary indicator of possible
sarcopenia, and confirmed with either the presence of low walking speed (<0.8m/s),
and/or low muscle mass assessed by whole body skeletal muscle mass index (also gender
stratified).9 The prevalence of sarcopenia was 13% overall, with 12% of males and 15%
of females presenting as sarcopenic at the time of transplant. These numbers are in
keeping with other reports of sarcopenia prevalence in the ESRD population, with rates
of 5.8% to 30.6% cited in the literature, using varying methods of assessment.1

QMLT represents an emerging measurement of muscle mass in the ESRD population,
and was thought to possibly serve as a source of bedside screening for the diagnosis of
sarcopenia. A significant proportion of the body’s overall muscle mass can be found in
the region of the thighs, justifying the targeting of this region as a surrogate measurement
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of total muscle mass.11 Berger and colleagues (2015) showed that in healthy community
dwelling individuals, QMLT values correlate with lower limb fat free mass (r = 0.74), as
well as total fat free mass derived from DEXA analysis (r = 0.71).7 In the critically ill,
Paris et al (2017) showed in a critically ill population that QMLT demonstrated moderate
correlation with the cross-sectional area of the abdominal musculature at the L3 level (r =
0.45).8 This relationship overall was largely driven by the young males, whereas the
correlation in young females, elderly females, and elderly males was not significant (r =
0.13, 0.24, 0.26, respectively).8 This suggests that QMLT may be applicable as a
surrogate measure in select populations. We found reasonable concordance between
QMLT and SMI, a measure of whole body muscle mass, but this relationship was not
seen regarding sarcopenia.

Several possible reasons may explain the lack of strong association between QMLT and
sarcopenia. Firstly, QMLT measures a single compartment of an appendicular muscle
group (anterior thigh). While this muscle group is important for locomotion, rising from
sitting, and balance, other muscle groups play significant roles in function as well, but are
not directly measured by the QMLT. In addition, muscle function defines sarcopenia,
with low muscle mass being a potential component.9 Changes to muscle mass reflected in
the QMLT may occur at a later time-point in sarcopenic progression, or distribution of
muscle loss may vary based on gender or age. Another consideration is that QMLT
measures the thickness of the muscle groups but not the total cross-sectional area of the
muscles of interest. Cross-sectional area may provide a better estimation of muscle mass
in the lower limb. In the healthy adult population undergoing resistance training, thigh
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muscle thickness on ultrasound had moderate correlation with changes in muscle crosssectional area on MRI (r = 0.69) after training, suggesting the muscle thickness alone is
probably a reliable index of muscle cross-sectional area at a given landmark. Thus,
measurement of QMLT versus cross-sectional area likely will not significantly impact the
relationships observed. Other groups have utilized multiple sites of ultrasound
measurement to estimate whole body skeletal muscle, including multiple areas of the
thigh and the upper arm, to increase the validity of ultrasound assessments of the
appendicular muscles.8 Lastly, QMLT does not provide a qualitative measure of muscle.
Myosteatosis, or fatty infiltration of the muscle, as well as fibrous infiltration of muscle,
results from muscle disuse and weakness, but does not necessarily compromise gross
approximations of size. Therefore, a muscle with significant myosteatosis may have
significantly worse functional potential compared to a similarly sized muscle with
minimal steatosis.22

Consideration should be given to potential population specific factors, such as fluid status
affecting QMLT measurements. Given that impaired management of fluid volume status
is a feature of ESRD, it is possible that muscle may swell/contract with
hyper/hypovolemic states which could vary from patient to patient depending on
adequacy of recent dialysis, dialysis modality, etc. Sabatino et al (2017) assessed the
reliability of QMLT measurement using bedside ultrasound in the critically ill population
with concurrent dialysis dependent severe acute kidney injury. In this cohort, when
QMLT measurements were compared pre- and post-dialysis, values did not significantly
differ. This observation was preserved regardless of whether conventional 4-hour
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dialysis or sustained low-efficiency dialysis (6-12 hours) was used, nor did degree of
weight change after dialysis impact QMLT measurements.12 The fluid shifts experienced
in the cohort of Sabatino and colleagues ranged from -0.5 to -3.0kg. In another cohort of
ESRD patients on hemodialysis, pre- and post-dialysis QMLT values did not significantly
differ. Thus it appears that fluid shifts likely do not impact the assessment of QMLT.

We found in our cohort of kidney and kidney-pancreas transplant recipients a prevalence
of sarcopenia of 13% overall (12% in males; 15% in females). This rate is in keeping
with or slightly lower than other published reports on sarcopenia in the transplant
population. Ozkayar et al (2014) showed in a cohort of patients who already received a
kidney transplant that sarcopenia was a prevalent in up to 20%, with a mean age of 44 in
the sarcopenic group and 36 in the non-sarcopenic recipients. Patients were assessed by
hand grip strength using weight based cut-offs from the Cardiovascular Health Study, and
BIA derived fat-free mass (not muscle mass per se).13

Fluid status is an important factor in BIA assessment. The resistance value provided by a
BIA analyzer is a measure that is inversely related to body water content.14-16 While raw
outputs from a BIA analyzer have been shown to be useful in predicting skeletal muscle
mass, the concordance of prediction equations to gold standard referent values may be
altered by significant fluctuations in total body water.17 Hydration status impacts the
measured resistance, and overhydration may mask muscle atrophy.1,18 Our protocol did
not standardize the timing of BIA analysis in relation to hemodialysis runs or peritoneal
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dialysis dwells due to practicalities of data acquisition, potentially reducing the internal
validity of this assessment. However, patients were assessed immediately prior to kidney
transplant whenever possible. Proceeding to the transplant operation typically requires
draining of the peritoneal dialysis fluid and displaying no acute indications for dialysis.
Therefore, it is thought the risk of underestimation of muscle mass may be minimal.

Another consideration is interobserver variability of QMLT measurement. QMLT
comes from point of care ultrasound measurement, and therefore is susceptible to
variability depending on the observer. Hadda et al (2017) sought to quantify the intraand inter-observer reliability of the QMLT assessed by ultrasound in the pneumosepsis
population and found that the intraclass coefficient (ICC) of the intraobserver variability
ranged between 0.835 and 0.925, with interobserver variability ICC of 0.992.19 Although
we did not specifically test for interrater reliability in our cohort, several reports have
demonstrated this modality to be reproducible across both expert and novice
assessors.20,21 Future studies using the QMLT in the kidney transplant population should
ensure measures of interrater reliability to add confidence to the internal validity in this
population.

The optimal mode of assessment for sarcopenia in the ESRD population remains in
evolution. The QMLT may not be a definitive stand-alone tool to replace other validated
clinical assessment instruments of sarcopenia, but could play a role in the armamentarium
of overall risk stratification of transplant recipients. Further study should be given to the
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various forms of identifying sarcopenia to validate the QMLT and other currently
available modalities in this population.
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Chapter 4

4

Comparing Metrics of Sarcopenia and Muscle Mass in
the Renal Transplant Population – Assessment of Test
Performance and Agreement

4.1 Introduction
Sarcopenia, or pathologic loss of muscle, in the end stage renal disease (ESRD)
population has been recognized as prevalent and has significant implications on the long
term outcomes of those on dialysis as well as those undergoing transplant.1, 2 Larger
muscle mass at the time of transplant has been suggested to portend improved survival
after transplant.1 Although there exists consensus criteria by several international
working groups, the most commonly cited diagnostic criteria for the diagnosis of
sarcopenias is that of the EWGSOP2.3 A drawback of the EWGSOP2 criteria is that
reviewed studies in the literature have largely excluded the renal failure/dialysis
dependent population. In the realm of renal transplant, there is a paucity of data reporting
on measures of muscle mass and function to confidently apply widely accepted criteria to
this population.

In previous chapters, the EWGSOP2 criteria was applied to a prospective cohort of renal
transplant recipients to detect the presence of sarcopenia, however no instruments have
been validated specifically in this population. The QMLT has demonstrated association
with prolonged length of stay in hospital, as well as shown discrimination for estimates of
low overall muscle muscle mass. Some of the metrics used for ascertaining sarcopenia
have been applied as part of frailty testing with good validity, namely grip strength and
walking speed.4, 5
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Cross-sectional imaging in the form of whole body CT or MRI has been considered a
gold-standard reference for quantifying skeletal muscle content.3, 6 Whole body MRI or
CT is costly, carries extra risk, and is not universally available. Segmental assessment of
the body’s compartments, such as the mid-thigh, arm, or torso7 may serve as surrogate
measurements that correlate with total body skeletal muscle. However, these forms of
imaging have the drawback of being outside of usual clinical practice and thus may suffer
from the same drawbacks as whole body imaging.

4.2 Purpose and Hypothesis
The purpose of this chapter is to compare the agreement between different modalities of
sarcopenic assessment in the ESRD population undergoing transplant, including muscle
mass and functional assessments currently endorsed by the EWGSOP2 criteria as well as
the quadriceps muscle layer thickness (QMLT).

It was hypothesized that cross-sectional area (CSA) of the entire abdominal musculature
at L3 as well as psoas muscles would correlate with total body skeletal muscle index
(SMI) as determined by bioimpedance (BIA) analysis as well as QMLT.

4.3 Methods
This study involved a prospective observational cohort study performed at London
Health Sciences Centre University Hospital in Ontario, Canada. Accrual of patients
occurred from March 1, 2019 to Jan 1, 2020. All patients presenting for a kidney or
combined kidney-pancreas transplant were invited to participate, and were excluded if
under 18 years of age, had a pacemaker, were due to receive a concurrent liver or heart
transplant, or did not agree to participate. Participants had demographic data collected
which included age, gender, height, weight, BMI, type of donor, as well as clinical
assessment values related to the physical frailty phenotype described previously8, in
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addition to bioimpedance assessment used to derive whole body skeletal muscle mass.9
QMLT was measured as well according to the protocol described earlier in Chapter 2
and 3.

When CT scans of the abdomen and pelvis were available for recipients, these images
were analyzed for skeletal muscle mass. CT image data sets were imported from AGFA
Healthcare PACS (Version 8.1.2) into Aquarius Intuition Viewer (Version 4.4.13.P2 TerraRecon) to perform body composition analysis. Two consecutive axial image slices
at L3 vertebral level were selected for analysis. Skeletal muscle cross-sectional areas
(cm2) for each CT slice were measured by summing the appropriate density pixels in the
areas of interest. Two different areas of interest were utilized for analysis. In the first,
segmentation of all the skeletal muscles on an axial slice was performed; this included the
erector spinae, quadratus lumborum, psoas, internal and external obliques, transverse
abdominus, and rectus abdominus muscles. In the second, segmentation of the bilateral
psoas muscles alone was performed. Boundaries for the two areas of interest were
manually defined for each slice by a subspecialty-trained musculoskeletal radiologist. A
CT Hounsfield unit (HU) range of -29 to +150 was used to defined skeletal muscle.
Measurements of the cross-sectional area of skeletal muscle for both the “total muscle
cross-sectional area” (CSAAbdoL3) and “psoas cross-sectional area” (CSAPsoasL3) were
performed for each axial slice and then an average of the two slices was obtained for each
of the respective cross-sectional areas (Figure 14).
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A.

B.
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Figure 14. Representative CT image at L3 showing definition of area of interest and
area of muscle identified by TerraRecon software based on HU parameters of -29 to
150. A. Psoas cross-sectional area, B. Total abdominal cross-sectional area

CT images were not obtained for the purposes of research. All CTs were done in the
context of clinical indication to assess vascular or intraabdominal organ anatomy to aid in
surgical preparation for transplant or assess patients for cause. CT images obtained in the
peri-transplant period (upon admission, post-operative) were deemed eligible for
inclusion in the analysis as it was considered that these perioperative images would still
provide reliable representations of the skeletal muscle mass possessed by recipients at the
time of transplant. CT images were not included in the analysis if the L3 region was
incompletely imaged, edema was too significant to reliably distinguish regions of interest
for muscle area determination, or defects in the abdomen were present due to surgical
complication (such as CT done for massive dehiscence obscuring the contours and
boundaries of the abdominal wall musculature).
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Statistical analysis was performed using SPSS v 26.0. Kolmogorov-Smirnov testing
assessed for the assumption of normality of the analyzed data. Demographic data was
collected relating to age, gender, and presence of sarcopenia. These values were
compared between gender groups using unpaired t-test and Fisher exact testing where
appropriate. The primary analysis was construction of a correlation matrix of the various
measures contributing to the assessment of sarcopenia according to the EWGSOP2
criteria. When variables satisfied assumptions of normality Pearson correlation was used,
and when normality assumptions were violated the Spearman correlation was employed.
The variables included measures of muscle function (hand grip strength, time to walk 15
feet converted to walking speed), muscle mass (skeletal muscle index [SMI] derived from
bioimpedance analysis9), CSAPsoasL3, CSAAbdoL3, as well as the QMLT. ReceiverOperator Curve (ROC) analysis was performed to assess the performance of the CT
derived metrics in predicting the presence of sarcopenia. Sarcopenia was deemed present
when low HGS based on gender-stratified cut-offs was identified, and the presence of
either slow walking speed (<0.8m/s) or low skeletal muscle mass based on accepted SMI
cut-offs.3, 6 Finally, the agreement between CT metrics (CSAPsoasL3/AbdoL3) and the
classification of low SMI and sarcopenia was assessed using a Kappa score for each test.
Cut-offs of the 25th and 50th percentile for both CT metrics were tested for agreement
with the classification of low SMI (based on the threshold for sarcopenia classification),
as well as for sarcopenia itself. Alpha was set to 0.05 for all analyses.
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4.4 Results
Forty four of 79 patients in our observational cohort had CT scans of the abdomen/pelvis
performed prior to, or shortly after their transplant, that were of adequate quality for
assessment. Table 8 contains the gender stratified values of CT metrics and rates of
sarcopenia. Fewer females were sarcopenic numerically, however this did not meet
statistical significance. The median time between CT scan and transplant was 56 days
prior to transplant, with 14 of 44 having a CT performed greater than 6 months
beforehand (range 187-602 days pre-transplant), while 16 of 44 had a CT performed after
the transplant (range 1-130 days post-transplant). The remaining patients’ CT scans were
performed between 1 and 167 days before surgery (median = 63 days).

Table 8. Gender stratified values of age and CT derived metrics of muscle mass at
L3 and sarcopenia
Male

Female

N

30

14

Age (yr)

51.4 (13.6)

50.2 (14.5)

0.79

CSA Abdo L3 (cm2)

159.9 (28.7)

114.8 (22.6)

<0.001

CSA Psoas L3 (cm2)

22.6 (5.6)

14.2 (2.7)

<0.001

Sarcopenia (%)

6 (20%)

1 (7%)

0.65

Values for Age and CSAAbdo/PsoasL3 are presented as mean (S.D.)

p-value
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All 30 males had both CT and adequate data to classify sarcopenia, while only 8 of 14
females had complete data. Subsequent analysis was only completed for the males in the
cohort due to lack of assessable data in female participants.

Table 9 displays a correlation matrix comparing the univariate correlation of the
individual components of sarcopenia classification, the CT derived metrics, and the
QMLT. Hand grip strength (HGS) was significantly correlated with gait speed/walk time,
CSAPsoasL3, and CSAAbdoL3. CSAAbdoL3 was most strongly correlated with the CSAPsoasL3,
and was followed by total body SMI derived from BIA parameters. QMLT showed no
significant correlation to any of the sarcopenia/CT parameters.

Table 9. Correlation matrix of sarcopenia parameters, CT measures of muscle mass,
and QMLT
HGS

Walk time

SMI

CSA Psoas L3

CSA Abdo L3

QMLT

CSA
HGS

1.0

-

-

-

-

-

Walk Time

-0.34**

1.0

-

-

-

-

SMI

0.25

0.08

1.0

-

-

-

CSA Psoas L3

0.57**

0.02

0.28

1.0

-

-

CSA Abdo L3

0.64**

-0.01

0.51*

0.71*

1.0

-

QMLT

0.08

-0.11

0.19

-0.02

0.14

1.0

CSA

* indicates p<0.05 for Pearson correlation coefficient
** indicates p<0.05 for Spearman correlation coefficient
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Receiver-Operator Curve (ROC) analysis assessed the performance of the CT metrics in
predicting sarcopenia. Table 10 contains the associated Area Under the Curve (AUC)
values for both metrics as well as age, a known contributor to sarcopenia. The CSAAbdoL3
demonstrated good performance in predicting the presence of sarcopenia with an AUC of
0.81 (95%CI: 0.66-0.97, p = 0.02). CSAPsoasL3 and Age did not significantly predict
sarcopenia, although age approached the level of significance. The ROC curves for the
performance of CSAAbdoL3 is depicted in Figure 15 and 16. The non-significant ROC
curves are not displayed. The cut-off point for optimal performance of CSAAbdoL3 was
155cm2, which was associated with a sensitivity of 83% and a specificity of 74% for
predicting sarcopenia. Changing the cut-off to 159cm2 (the median measurement)
increased sensitivity to 100% while specificity decreased to 65%.

Table 10. Areas under the curve for CT metrics and age for identifying sarcopenia
and skeletal muscle index below gender-stratified cut-offs
Variables

AUC

p-value

95% CI

CSA L3 total : Sarcopenia

0.81

0.02

0.66-0.97

CSA L3 psoas : Sarcopenia

0.52

0.87

0.25-0.79

Age : Sarcopenia

0.72

0.06

0.50-0.95

CSA L3 total : Low SMI

0.74

0.03

0.53-0.95

CSA L3 psoas : Low SMI

0.48

0.88

0.26-0.71

Age : Low SMI

0.50

0.97

0.29-0.70
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Figure 15. Receiver operator curve of cross-sectional area of total abdominal
musculature at L3 as a predictor of sarcopenia
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Figure 16. Receiver operator curve of cross-sectional area of total abdominal
musculature at L3 as a predictor of low skeletal muscle index

The agreement between the CT metrics at the 25th and 50th percentile cut-offs and low
SMI and sarcopenia was assessed using Kappa scores and is outlined in Table 11. The
greatest agreement in testing occurred between the 25th percentile CSAAbdoL3 and low
SMI, followed by the 50th percentile of CSAAbdoL3 and sarcopenia. Both Kappa values
suggest modest agreement between the test modalities.
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Table 11. Kappa statistics testing for the agreement between CT metrics of muscle
mass at 2 cut-offs and sarcopenia, skeletal muscle index below gender-stratified
thresholds
Comparators

Kappa

p-value

CSA L3 Psoas - 25%ile vs. Low SMI

0.054

0.76

CSA L3 Psoas - 50%ile vs. Low SMI

0.096

0.8

CSA L3 Total - 25%ile vs. Low SMI

0.53

0.003

CSA L3 Total - 50%ile vs. Low SMI

0.37

0.04

CSA L3 Psoas - 25%ile vs. Sarcopenia

0.11

0.55

CSA L3 Psoas - 50%ile vs. Sarcopenia

-0.13

0.44

CSA L3 Total - 25%ile vs. Sarcopenia

0.31

0.096

CSA L3 Total - 50%ile vs. Sarcopenia

0.44

0.004
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4.5 Discussion
In our prospective cohort of kidney/kidney-pancreas transplant recipients, the level of
agreement between muscle mass assessment using CT scanning and other clinical
measures of muscle mass and sarcopenia were compared. Cross-sectional area of the
entire abdominal musculature at the level of L3 (CSAAbdoL3) correlated the best with nonstructural assessment of muscle (HGS) as well as other methods of muscle mass
estimation (CSAPsoasL3, SMI derived from bioimpedance analysis). CSAAbdoL3 also
showed good performance as a predictor of sarcopenia at a cut-off of 155cm2 carrying a
sensitivity and specificity of 83% and 74%, respectively. The good performance of CT
was only demonstrable in males, however, owing to lower numbers of females with
available CT scans. The reliability of CT in female transplant recipients remains
unexplored in this population. On the other hand, QMLT did not significantly correlate
with any of the metrics recommended for assessment of sarcopenia by the EWGSOP2
criteria.

The importance of sarcopenia has emerged in the context of solid organ transplants
outside of kidneys. Hsu et al (2019) showed that sarcopenia in lung transplant recipients,
defined as a psoas CSA indexed to height, significantly predicted 1, 2, 3, and 4 year
mortality.10 To derive normative values, gender-based cut-offs were defined from their
internal cohort based on scatterplot smoothing and spline modeling. van Vugt et al (2016)
demonstrated in a systematic review and meta-analysis of liver transplant recipients that
sarcopenia independently increased the risk of both wait-list and post-transplant
mortality.11 Based on growing reports of the influence of sarcopenia in non-renal
transplant populations, the importance of being able to identify sarcopenia in the renal
population becomes evident.

The impact of sarcopenia in renal populations has been highlighted in the literature. Lai
et al (2019) described a sarcopenia prevalence of 49% in a prospective cohort study of 77
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CKD patients, with half requiring renal replacement therapy in the form of dialysis.12
They found that sarcopenia was significantly associated with increased intima-media
thickness, a marker of atherosclerosis and cardiovascular risk and flow-mediated dilation
of the brachial artery, a measure of endothelial dysfunction. Montreal Cognitive
Assessment (MoCA) scores were significantly lower in the sarcopenic group and
depression was more prevalent, suggesting a link between sarcopenia and cognitive
decline and depression. These authors defined sarcopenia using HGS and Janssen’s
SMI12, similar to our current study. Our prevalence of sarcopenia was much less than that
reported by Lai and colleagues, possibly due to the older age of their cohort (mean age
69). Despite divergent demographics, their findings suggest that sarcopenia may be an
important factor to screen for in the ESRD/transplant population, beyond the concerns of
perioperative/post-transplant outcomes.

Kittiskulnam et al (2017) found in a prospective study that sarcopenia per se did not
significantly impact the risk of mortality in a maintenance hemodialysis population of
645 patients, nor did any measurement of muscle mass based on bioimpedance
spectroscopy.13 Functional measures of muscle, including gait speed and grip strength
(components of sarcopenia case definitions) did, however, significantly impact survival.
The addition of any muscle mass covariates did not improve the predictive value of
functional measures. These results emphasize the importance of functional measures of
muscle. Giglio et al (2018), in an observational cohort study of 170 maintenance
hemodialysis patients measuring muscle mass with BIA, found lower muscle strength and
sarcopenia significantly increased the risk of experiencing hospitalization (aRR = 1.92
and 2.08, respectively) as well as overall survival (aRR = 1.84 and 2.09, respectively).14
These authors maintained case definitions of sarcopenia congruent with EWGSOP2
criteria, utilizing appendicular skeletal muscle mass and HGS as defining criteria,
however gait speed was not included. Lower muscle mass in isolation, however, was not
significantly associated with either overall survival or hospitalization.
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Hand grip strength in our cohort significantly correlated with another parameter of
sarcopenic assessment: walking time. Additionally, HGS showed significant correlation
to CSAL3Psoas and CSAL3total. Functional measures may seemingly offer cheaper and more
accessible solution to screening for sarcopenia in the clinical setting than more expensive
cross-sectional imaging. Chan et al (2019) longitudinally studied 128 kidney transplant
recipients who were ≥1 year post transplant with a functioning graft, placing patients into
a sarcopenic or non-sarcopenic group. The authors defined sarcopenia by the presence of
both low HGS and low muscle mass based on population normative values provided by
the manufacturer of the BIA machine used in their study. They found that at a median
follow up of 64 months, low strength was independently associated with their composite
endpoint of mortality or hospitalization, while neither low muscle mass nor sarcopenia
were significantly predictive of these outcomes.15 The superior performance of grip
strength supports the need for clinical testing of muscular function in this population. The
apparent lack of prognostic significance seen by Chan et al. in relation to muscle mass is
challenged by the case definitions of low muscle mass and sarcopenia. Their surrogate
measures of muscle mass were not derived from regression equations validated in the
literature, nor were the EWGSOP2 or any other published criteria used to assess
sarcopenia.

The importance of standardizing or defining thresholds for muscle mass, as well as
uniform agreement on case definitions of sarcopenia, are important. This was highlighted
by Lamarca et al (2014) in a multicentre cross-sectional study, where a wide range of
sarcopenia prevalence was found depending on the modality and cut-off implemented.
With BIA + HGS derived case definitions, prevalence ranged from 12.7% to 45.1% with
the BIA cut off at 20th%ile and 2 S.D. below young population norms, respectively.16 The
BIA formula used to derive skeletal muscle mass estimations was not described, limiting
the ability to confidently compare these authors’ findings to our own and others in the
literature.
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Whole body cross-sectional imaging is considered the gold-standard referent for
measuring muscle mass6, but in its stead single slice images have been used in several
research settings. One area of interest in cross-sectional imaging has been the psoas
muscle as well as more expanded views of the abdominal musculature.10, 17, 18 We chose
to examine both the psoas CSA and entire abdominal muscle CSA to explore the relative
performance of both metrics.

Morrell et al (2016) interrogated the performance of cross-sectional imaging in
maintenance hemodialysis patients to predict low muscle mass. They used MRI at the
level of the mid-thigh and the L4-5 level compared to whole body lean mass derived
from DEXA measurement. Overall, total CSA of the mid-thigh was the greatest predictor
of whole body lean mass, followed by psoas muscle cross-sectional area.18 Furthermore,
these authors demonstrated that mid-thigh muscle CSA was highly correlated with psoas
CSA at L4-5 (r=0.83), and the AUC for psoas CSA for predicting sarcopenia was
between 0.81 and 0.92. Sarcopenia was defined using two different percentile cut-offs
based on their cohort DEXA estimations of lean body mass, rather than EWGSOP2
definitions, which rely on consideration of some measure of muscle function in addition
to mass. Nevertheless, Morrell and colleagues show that psoas muscle CSA at L4-5 in the
dialysis population was predictive of total muscle mass.

Our results, however, did not support such a strong relationship between CSAPsoasL3 and
total muscle mass. In fact, our data suggest that a relatively poor discriminatory capacity
for psoas CSA to predict overall muscle mass with an AUC of 0.48. The reasons for this
discrepancy are several-fold. Firstly, we assessed psoas CSA at the L3 level which is
higher than the level studied by Morrell et al. This is relevant when one considers the
mean CSA of the psoas in our population was 19.9cm2 (22.6cm2 males; 14.2cm2 females)
while the mean CSA of the psoas in the report by Morrell was 10.4cm2. The difference
between measuring at L3 vs L4-5 may have accounted for this variation, as the psoas
tapers in circumference as it passes inferiorly to insert onto the lesser trochanter of the
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femur. Whole body muscle mass was assessed in our study using regression equation
based off BIA parameters validated in the literature for the general population with
recommended cut-offs from the EWGSOP19, 20, whereas Morrell set cut-offs of the 10th
and 25th percentiles of total lean body mass based on DEXA scans. Assessing the
performance of any single slice image is clearly dependent on consistent case definitions.

Shen, et al (2004) identified that in healthy subjects, the cross-sectional area of the entire
abdominal musculature at a position of 5cm above the L4-5 level (approximately L3),
was highly correlated with measures of total skeletal muscle volume using standardized
whole body scans (Pearson correlation, r = 0.924).21 When other covariates were added
into a multivariable prediction model, the addition of sex, age, BMI, and waist
circumference only improved the R2 by 2.3-3.3%, suggesting the single-slice image may
be used to represent total body skeletal muscle reliably.21

Giglio et al (2019) looked at patients with chronic kidney disease (of which 70% were
stage 3-4) using CT to derive CSA at the L3 level of the entire abdominal musculature
and SMI using bioimpedance measures (using the Janssen formula). They found a Kappa
of 0.41 and AUC of 0.70 (0.60-0.81), with r = 0.51 (Pearson correlation) in males
comparing these two measurements.7 These results compare favorably to the reported
outcomes of the current study. Our population of end-stage renal patients undergoing
transplant demonstrated CSAAbdoL3 provided an AUC of 0.74 (0.53-0.95), with r=0.51 on
Pearson correlation. The concordance of this CT metric in both the pre-dialysis CKD
population and ESRD population undergoing transplant supports the validity of this form
of testing in renal populations, and supports the utility of CT-assessed muscle mass
across several stages of renal disease.

Quadriceps muscle layer thickness, an emerging measure of muscle mass in the literature,
correlated poorly with functional components and structural components of sarcopenia
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assessment (Table 9). The poor performance of QMLT as a predictor of sarcopenia was
explored in Chapter 3. With minimal correlation between QMLT and CSAPsoasL3/AbdoL3,
the enthusiasm to further explore this metric as a surrogate for sarcopenia becomes
tempered. This finding is contrasted by other studies demonstrating high concordance
between mid-thigh muscle area and psoas CSA.18 An important differentiator is that
QMLT measures the thickness of the anterior compartment of the thigh (rectus femoris,
vastus intermedius muscles), while other studies correlating the thigh and psoas have
utilized cross-sectional area.18 Previous studies have demonstrated concordance of
QMLT and psoas CSA on CT, however. This positive relationship has been demonstrated
in the young male critically ill population, with poor correlation in critically ill females
and the elderly.23 Thus, QMLT may have selective applicability to identify clinically
vulnerable subpopulations. Expanded study of the QMLT in concert with other accepted
metrics of sarcopenia are needed to better define this role.

Another consideration that both total CSA and muscle compartment thickness do not take
into account is the quality of the muscle, namely intramuscular fibrosis or adiposity from
disuse/disease and other derangements of muscle architecture.22 Fukuda et al (2018)
retrospectively assessed 41 pancreas transplant recipients with CTs done at the time of
transplant for the presence of sarcopenia defined as a psoas muscle index (cross-sectional
area indexed to height) at the level of the umbilicus below the lowest quantile in the
cohort, and found that sarcopenia did not worsen the risk of complications or graft
survival.17 These authors also assessed intramuscular adipose content on the same CT
scans, and found that adipose content of the multifidus muscles significantly increased
the odds of complications. The adipose content was only moderately associated with
psoas muscle index (r = -0.51). Taken together, the relative importance of muscle quality,
over and above the gross size in the form of cross-sectional area or volume, may underpin
the imperfect relationship between sarcopenia and CT-derived metrics in the present
study. In addition, the distinction of muscle quality may be a more telling metric to
consider in future research.

96

This study does have significant limitations that require consideration. CT scans were not
available for every patient, limiting our sample size for analysis. Systematic bias around
those with and without indications for CT are not able to be accounted for because of
this. Additionally, the date of CT scan and transplant were inconsistent across the cohort,
introducing uncertainty to the findings, as the effect of time on changes to muscle mass
are not accounted for due to lack of serial imaging. Paris et al (2017) found that QMLT
was well correlated with CT derived measures of the psoas muscle in the critically ill
when the QMLT and CT were done an average of 1 day apart.23 Bioimpedance analysis
also carries inherent flaws as the values derived from BIA are influenced by hydration
status, a significant consideration in the mostly dialysis dependent population undergoing
transplant. Due to logistical constraints, timing of BIA was not standardized relative to
dialysis runs and therefore may introduce variation in the results not able to be accounted
for. On balance, a strength of our study is that we maintained validated case definitions of
sarcopenia and cut-off values from the sarcopenia literature. This is also the first report to
the authors’ knowledge of assessing metrics of sarcopenia/muscle mass in the ESRD
population at the time of transplant.

In summary, CTAbdoL3 demonstrated good predictive ability to identify sarcopenia.
Further exploration of this metric in the kidney transplant population is warranted to
better characterize population normative values as well as gender-specific thresholds to
define low muscle mass for standardization in future studies. These measurements should
be maintained within the context of muscular function, as is suggested by consensus
guidelines on defining sarcopenia. With improved definitions to operationalize
sarcopenia, the impact on clinical outcomes can be better studied and appreciated and
opens the door to rational interventions to impact populations at risk.
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5

General Conclusions and Future Directions

The impact of frailty and sarcopenia in renal transplant recipients has been established in
the literature, and is continuing to be refined over time. The literature has demonstrated
that frailty, assessed using the Physical Frailty Phenotype, significantly affects recipient’s
LOS, DGF rates, and influences survival, thus validating its use in the transplant
population.1-3 Sarcopenia is intimately related to frailty, acting as either a component of
the underlying pathophysiology of frailty or another manifestation of a common pathway
with frailty.

The QMLT has received attention in several contexts as an accessible surrogate measure
of frailty and/or sarcopenia that appears to be reliable in published reports.4-7 Our use of
the QMLT identified those at risk of longer LOS after transplant. It is possible that with
greater numbers of participants to allow stratification by donor type, statistical power can
be maintained to refine the influence of this metric on patient outcome. Further study of
the QMLT in the transplant population should be undertaken to expand on this finding,
and to refine the value of measuring the QMLT. We intend to expand on our number of
participants. QMLT in isolation did not show good discrimination for the assessment of
sarcopenia but was correlated with overall skeletal muscle mass using bioimpedance
derived calculations. It is possible this observation relates to the functional assessment
that underlies sarcopenia that is not captured by QMLT, which is purely quantitative.
While QMLT may not be a perfect tool as a one-time assessment, its value as a serial
measurement warrants exploration, as QMLT has shown reliability to detect changes to
resistance training over time11, and thus perhaps the dynamics of QMLT may be more
telling than a single absolute value.
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Muscle quality is another factor that deserves future study. All assessments in the present
study relied on gross muscle size estimations and clinical functional testing, but no
assessment of muscle architecture was included. Intramuscular adipose content, fibrosis,
density of mitochondria, exhaustion of muscle satellite cells, and degradation of motor
end plates could all represent significant factors that better inform a patient’s underlying
degree of sarcopenia/frailty.8, 9 These variables are not necessarily appreciable with
standard cross-sectional imaging, strength testing, and other available measurement tools
in clinical practice. Correlation between histologic and biochemical parameters of
skeletal muscle with currently available assessment tools, such as muscle density on
cross-sectional imaging, warrants exploration in the future.

It was seen in this study that cross-sectional area of all abdominal muscles at the level of
L3 had the greatest discrimination for sarcopenia. This finding is limited to males, as
there were insufficient females with complete data to allow for analysis. The variable
timing in administration of CT scans also possibly confounds our results. Future studies
should look to validate this CT metric by examining recipients’ muscle mass in a
systematic and controlled fashion to improve the validity of this metric in this population,
and to refine normative values. The impact of CT measurements of muscle on clinical
outcomes would then be considered with greater confidence. We hope to continue to
accrue patients in an ongoing effort to augment the number of patients with CT scans
available for assessment, however ethics board standards limits the ability to expose
potential recipients to CT scan radiation without clinical justification which could hinder
future numbers as it did in the present cohort. Regardless, greater numbers of CT-derived
metrics will allow for examination of these values and the relationship to clinical
outcomes, similar to the way QMLT was studied here.

Lastly, consensus on simplifying the definition of sarcopenia in the renal failure and
transplant population should be sought: current application of operational criteria for
sarcopenia in this population remains theoretical.10 This would achieve improved
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standardization of research protocols to allow confidence in comparing outcomes, and
would provide basis to help classify patients accurately in the clinical context for risk
stratification and intervention.

The impact of frailty and sarcopenia on outcomes of renal transplant are maturing and
gaining importance for consideration in the assessment of potential transplant recipients.
As the prognostic impact of these metrics is further clarified, an impetus to incorporate
formal testing into the assessment process for prospective transplant recipients arises.
The multitude of frailty instruments and different ways to assess the components of
sarcopenia potentially leaves clinicians and assessment programs at an impasse over
which method would be the most feasible and informative. The QMLT was assessed as a
potential surrogate for frailty and sarcopenia with the potential to be a single-step
assessment that could simplify the multifaceted testing of frailty and sarcopenia. This
report supports a potential role for the QMLT, but its validity remains to be confirmed,
and other forms of assessment such as CT of the abdomen along with possibly expanded
appendicular muscular assessment with ultrasound require further exploration to identify
valid cut-offs for clinical prognostication. The goal of finding a simple, feasible and
meaningful screening metric remains to identify those at greatest risk of complications.
Identifying such individuals would ideally lead to improved risk counselling and
potentially allow for invitation of these patients into therapeutic programs that may
involve prehabilitative exercise, pharmacotherapy, or dietary interventions that could
alter the progression of frailty and sarcopenia.
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Appendices

Appendix 1. Frailty phenotype data collection sheet and cut-off references for
strength, walk time, activity levels, exhaustion, weight loss
From: https://www.cgakit.com/fr-1-frailty-phenotype

FRAILTY PHENOTYPE
NAME

_________________________________________________

d.o.b.

_________________

Date

_________________

Administered by __________________________________________

CRITERIA

OPTIONS

Unintentional weight loss

Physical Activity

Low resistance/exhaustion

Strength

Walking Time

WEIGHT

SCORE

no
yes

0
1

______

Not limited or little limited
Limited a lot

0
1

______

0 to 2 days
3 to 7 days

0
1

______

< 20% weaker
> 20% weaker

0
1

______

Not slower
Slower

0
1

______

TOTAL SCORE

______

SCORING
0 = robust
1-2 = pre-frail
3-4 = frail
5 = very frail

NOTES :

1
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DEFINITIONS
Unintentional weight loss :
>5% weight loss over past year
or
>4,5 Kg weight loss over past year
Physical Activity :
Health imposes a limit on vigorous activities such as, mowing the lawn, raking, gardening, hiking,
jogging, biking, exercise cycling, dancing, aerobics, bowling, golf, swimming, other sport.
Low resistance/exhaustion :
Frequency that, in the past week, the individual felt that everything s/he did was an effort
or
s/he could not "get going"
Strength :
Without dynamometer :
Estimated 20% weaker than expected in an individual of similar size (BMI)
or
With dynamometer ( stratified by gender and Body Mass Index quartiles )
Men
BMI < 24
BMI 24.1–26
BMI 26.1–28
BMI > 28
Women
BMI < 23
BMI 23.1–26
BMI 26.1–29
BMI > 29

Cutoff for grip strength (Kg)
criterion for frailty
< 29
<30
< 31
<32
Cutoff for grip strength (Kg)
criterion for frailty
< 17
< 17,3
< 18
<21

Walking Time :
( stratified by gender and height )
Men
Height > 173 cm
Height < 173 cm
Women
Height > 159 cm
Height < 159 cm

Cutoff for Time to Walk 15 feet
criterion for frailty
6 seconds
7 seconds
Cutoff for Time to Walk 15 feet
criterion for frailty
6 seconds
7 seconds

2
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